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POST HOC QUANTITATIVE ASSESSLiENT OF DRUG SIDE EFFECTS 
--- - --------
IN'I'RODUCTI ON 
The prese nt study was undertaken to determine: 
1) whether data fron1 heterogeneous sources could be pooled 
and analyzed systematically to yield meaningful results, as 
if they had been collected as part of a prospective experi-
ment ; 2 ) what kinds of treatment of the data would produce 
usable results; and 3 ) vn~ether any of the results so obtained 
are sufficiently usable to pel'mi t any conclusions from them. 
The se propositions vYere applied to an effort to study retro-
spectively the nature of the toxic side effects of 
cllloramphenicol, trimethadione~ and strept omycin on the b one 
marrow~ and of streptomycin, dihydrostrept omycin, and 
neonzycin on the eighth cranial nerve by using the available 
published literature as sources of the data. 
ldany pharmacol ogical agents produce one or more side 
effects, that is, drug effects other than those for which 
the agents are administered. These effects may b e desirable 
or undesirable; if they al'e undesirable, they are called 
toxic side effects . The incidence, kind, and severity of 
drug toxicity vary among different effects, different drug 
classes, and different drugs . Drug toxicity may be pre -
di ct able with some agents and not with others. It may or 
may not be dose-dependent, allergic, or idiosyncratic. 
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Five drugs, chosen from two drug classes and exhibiting 
two different side effects, were studied, in ord~r to pro-
vide overlap between dru8s, parent drugs, drug classes, and 
their side effects, for purposes of comparison: 
DRUG CLASS 
Antiepileptics 
Antibiotics 
fl 
fl 
fl 
fl 
DRUG SIDE EFFECT 
TRil'iETF~DI ONE BOl\TE l'.TARROW 
CHL OR.li.MPHENI COL BONE MARROW 
STF..EPT Ol'i:YCIN BONE MARROW 
S TREPT OI\IYCIN OTOTOXICITY 
DIHYDROSTREPTOMYCIN OTOTOXICITY 
1JEOI.JYCIN OTOTOXICrrrY 
DEPRESSION 
DEPRESSION 
DEPRESSION & 
-3-
MATERIALS .AND I>.:JETHODS 
COLLECTION OF DATA 
The American 1 British, French, and German li te1•ature 
t h rough 1961 was searched for re ports of cases of toxici ty 
r esu l t i ng from the a dministration of chloramphenicol (1-28 ), 
tr.i rnethadJ.one (29-44), streptomycin and dihydrostreptorrwcin 
(55-101), and neomycin (102-114). The diagnoses of t he 
phys i ci ans r epor ting the cases were accepted, but in order 
to be include d in the tabulation, certain criteria h ad to 
be met. The primary criterion was presumptive evi dence for 
a single drug effect for each drug . 
For chloramphenicol, an additional criterion for in-
clus ion was the development of aplastic anemia (pancytopenia), 
di agnosed by bone mar row biopsy or autopsy specimens. Only 
ca ses with depression of all three formed elements of the 
b lood were included in the statistical analyses, and cases 
of anenu a , granulocytopeni a , or thrombocytopenia a lone or in 
combina tions of any two only were not included. However, 
case reports of patients with depression of one or two bell 
t ype s onl y were collected separately . Cases of bone ma r row 
suppression r e sulting from trimethadione or streptomycin 
adm:inistrat .ion were included. as long as at least one blood 
element was reduced. The criteria for the di agnosis of 
ototoxicity resulting from the administration of strepto-
mycin, dihydrostre ptomycin, or neor,wcin, were the occurren ce 
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of acoustic dysfunction (deafness ) or vestibular impairment 
(vertig o, ataxia, or diminished response to caloric stimula-
tion), OI' both. 
Table I shows the nur.11ber of cases reported pei' publica-
tion for each drug . The frequency distributions were such 
that no one publication could unduly in£luence the data for 
any one drue with the possible exception of dihydrostrepto-
mycin . 
The following data were recorded and tabulated for each 
patient: age, sex, race, disease for which the drug was 
prescribed, dose schedule and duration of drug administra-
tion, number of courses of drug, t .ime fl"om cessation of 
drug administration to onset of symptoms of side effect 
(which was generally within 3 to 5 days of the diaenosis of 
drug toxicity), death or survival , time of survival fror:1 
onset of symptoms in those who died, and cause of death . 
For patients with bone marrow de pression following adr~unis­
tration of chlors.mphenicol, trimethadione, or streptomycin, 
the following data concerning peripheral blood were re corded: 
hemoe lobin concentration (grams per 100 ml ) , white-cell count 
(per cubic 111i llimeter), percentage of polymorphonuclear 
leukocytes, and platelet count (per cubic rnillimeter) . These 
data v1ere taken from laboratory d2.ta obtai ned at the time the 
patients first colilplained of or manifested signs of bone 
marrm'/ depression, since such data had b een obtained by the 
reporting physician a l most uniformly for each patient, in 
- 5 -
contrast to finding s at any other time during the course of 
tlJ.e pati ent 1 s toxic effects. Data ob t a ined before treatment 
wi th the drugs were not e;e nerally available, so that .it was 
not possible to study the change in blood cell elements after 
administration of the drug . For patients with ototoxici ty 
following administration of s treptomycin, dihydrostreptomycin 
or neonzycin , onl y t he presenc e or abs ence of deafness and/or 
vestibular dysfunction were re c orded, since whatever audio-
metr1.c and caloric stimulation data were given were obtained 
by different methods and presented in ways precluding con-
version to any s tandardized form, though the loss of h e a ring 
in decibels was reported for one l a r ger series and t hese 
data 1ere recorded. 
i FPI'I?TE./) 
Some data were arbit rarily converted from"value s t o 
common tmi ts. m1.e:1ever l"lemoglobin concentrat i on values were 
r eported as per cent, t hey were converted t o crams per cent, 
using a standard of 15 . 0 g rams as the 100 per cent value . 
Since body weights were not given for most of the patients 
reporte d , they vvere estimated f or al l of t:Qe pat.i ent s 
studied from standard age-weight t ables (135), in order t o 
calculate the data on a c ormnon basis . Neomy cin doses we i'e 
converted fro:tE units , as they appeared in the olc.er litera -
ture, and from g rm!ls of neomycln sulfate, a s they· appear in 
the more recent data , to .~_; rams of pure neomycin base ( 1 graL 
of neomycin sulfate equals 0 . 7 gr ams of pure ne omycin base) . 
The dose administerGd t o the tvro patients who rece"ived 
-6-
neomycin orally was estimated as 3 per cent of the oral dose, 
the upper li rnit for gastro.intest.inal absorption (128). 
For all drugs the patients were segregated .into groups 
by dose metameters calculated from the available data as 
total dose (g rams), total dose per kilogram estimated body 
we .ight (milligrams), and dose per kilogram estimated body 
weight per day (rnilligrat"TTs). 
For each drug, vn1en the nunmer of reported cases per-
mitted, the relationship of the patients' age and sex to the 
occurrence of the side effect was determined after segre -
gating the patients into subg roups, first according to sex 
but without regard to age, and second according to age but 
without regard to sex. Hence, each pat ient was represented 
.in both tabulations, but only if both properties of the pa-
t'i.ent 1.11J'ere known . In segregating the pat ients according to 
age , class intervals were constr•ucted so that at least seven 
patients were in each. The class limits differed from drug 
to drug and are given in the appropriate tables below. 
Similarly, fol~ chloramphenicol alone, the influence of 
interl'lrl.ttency of therapy and the outcome of the aplastic 
anemia (recovel~y o1~ death) on the occurrence of t£1e side 
effect was analyzed after appropriate segregation of the 
data .. For streptomycin, dihydrostreptonrycin, and neomycin, 
the relationship between the form of ototoxicity rnanifested 
in the patients (acoustic and/or vestibular dysfunction) 
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and the occurrence of the side effect was analyzed after 
appropriate seg regation of the data. 
For streptomycin and dihydrostreptomycin alone, another 
series of data was collected for patients .in wh om ototoxicity 
occurred following drug administration (55-101). These data 
were for groups of patients including no individual patient 
data . Reported percentage incidencesof occurrence of acous-
tic and/ol~ vestibulai' impa.irment were recol""ded for patients 
receiving specified dose levels per day of the two drugs, 
as wel l as duration of therapy~ without regard for differ-
en ces between patients (e.g., in age, sex, et c.), which 
were, in general, not reported for the patients included in 
the series .. 
METHODS OF ANALYSIS OF DATA 
Occurrence of Side Effects 
For each drug the median of t h e closes which were ef-
fective in producing t he associated side effect, in all 
patients manifest .ing the side effect, was computed . The 
method .involved substituting dose for time in Litchfield's 
nomographic method for solving tL~1e-ml .. mulatlve per cent ef-
fect curves (129). In this method, cu~1ulative per cent 
frequency of response to a drue; was plotted, as probits, 
against the logarithm of the dose or duration or drug ad-
ministration. For e ach drug , the c~m1ulative incidence of 
the side eff ect was the response studied. The expression 
CED50, t he median Cumulative Effective Dose, and CET50, 
-8 -
the median Cu .. mulative Effective Time of drug adrainistration, 
denote values obtained by interpol ation from t he line. 
Linearity was tested using the variance ratio, F, as out-
lined by Snedecor (134 ). 
The results were tabulated as follows, for each drug, 
side effect, and subg roup of patients : 
N is the number of patients in the subgroup . 
CED50 is the median of the doses which were effective 
in producing the side effe c t in the subsroup . This cor-
responds to the median dose in the frequency distribution 
of doses . 
CET50 is the median of the pel~iods of drug administra-
tion vvhich were effective in producing the side effect in 
the subg roup, and c orresponds to the :median duration of ad-
nunistration in the freq_uency distribution of dtn~ations of 
administration. 
S is the Slope Function , the anti log aritlun of the re -
ciprocal of the slope , wh-ich represents the fold chang e in 
dose, or time of drug administrat i on, required to produce a 
unit stfu"ldard deviation change in response along the curve -
S corres ponds to the s t andard deviation of the original fre -
quency di stributj_on of doses or t imes of administrat t on . 
95~6 C. L . is the 95~;s Confidence Limits for the CED50, 
CET50, or S, and indicates the values between w!:J..ich 955~ of 
val ues for the CED50, CET50, or S wmJ..ld fa l l for an j_nfini te 
nuJnber of sinular S8~pling s . 
- 9-
PF is the probability that the arrangeraent of points 
which deterntlned the curve differed significantly fr om a 
straight line . 
Tb.e statistical significance of differences between 
CED50 1 s, CET50's, and slope functions, in various c6mbi-
nations of subgroups, vvas determined as outlined by 
Litch field, using ratios of tb.ese values to each other and 
I 
comparing functi ons of the values with the nornographs con-
structed for the purpose . Statist:i.cal diffe rences in slope 
functions we:c•e taJ.m n to indicate lack of parallelism of the 
lines compared. Probability levels accepted as indicating 
statistical significance of differences were taken to be 
.05 unless otherwise specified. 
For streptomycin and dihydrostreptomycin, the doses 
an.d durations of drug administration which were. effective in 
producing the respective side effects in 50 per cent of all 
patients to whom the two drug s were adminis tered , wer e com-
puted . These median doses (ED50) and times of drug 
adn inistx:ation (ET50) are to be cont rasted with t h ose whose 
computation is described above (CED50 and CET50) . The 
nomogl'aphic method of Litchfield and Wilcoxon ( 130) used to 
compute t hese values is based on plots of the percentage of 
responders , in probits, at each dose and time level, against 
the los ari tf1...rn of the dose or time. A no:mographic method 
(130) for determining chi-square values was used to determine 
if the data were not significant l y heterogeneous, i.e., 
-10-
w:!:lether the line was a g ood fit . 'D1.e data used we1•e those 
for g roups of patients treated •.vi th str•eptonrycin and di-
hydrostreptornycin, and not those for individual patients 
who were selected because they showed the side effects and 
from whose data the CED50 and CET50 were calculated. 
To dete1•mine the percentage of patients ·who responded 
at each dose level ol"' pe1•iod of drug therapy, the data from 
all papers pertaining to that dose level or the rapy period 
were pooled by adding togethel"' a l l patients tree.ted with 
the drugs who developed the side effects , and dividing that 
nurnber by the total number of patients treated with the drug s . 
The CED50, then, sunrrnarizes the frequency distr.ibution 
of doses; the ED50 summarizes a dose-effective cure . 
Biotransfor~mtion and Excretion of Chloramphenicol 
For chloramphenicol only, raw data from the literature 
(120, 121, 125) were studied to deterntlne the rates of 
urinary excretion and disapperance from the blood of 
chlors_mphenicol , its inactive metabolites , and the sum of 
the two expressed as total nitro compounds, s ince both 
micl"'obiologi cally actlve chloramphenlcol and its metabolites 
contain nitro gr oups . Data s t udied were restri cted to data 
fo1• human subjects who rec ei ved sing le doses of the drug . 
From the rates of urinary excretion it was poss i ble to 
compute, with the formulae described by Wells (138), the 
maximum total amounts of chlorampheni col, its metabolites, 
and their sum, obtainable in the body with chronic 
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administration of the drug . From the plasma levels could be 
computed the maximum total amounts of chloramphenicol, :its 
metabolites, and their sum obtainable in the plasma with 
clu·onic administration of the drug . !1/Iaxi:rm.un amounts re-
:mD.ining 24 h ours after withdrawal of the drug from chronic 
administration could also be dete rrdned . A cor.1parison of 
data for the persistence of t he chemical s in the bod~r and 
in the pl a sma could then be made . 
For each subject the data for urinary excretion were 
plotted as per cent of the total amount of each cherrical re -
covered whi ch remained in the body at various time intervals 
after dr1..1.g adr1ini stration . With the method of Davis ( 117 ) , 
the curve s wel"e rectified to fit the curve of the equation 
y~ lO~HbX + c, in which x is the time after administration 
of the drug , X is the per cent of t he amount finally re-
covered which was not excrete d , or which remained in the 
body at time X _, a is the intercept, b is the slope, and£ 
is the value of X a t which the cu rve is asymptotic with an 
abs cissa drawn at that value and corresponds to the maximum 
amount of material which can never be recovered from the 
urine regardless of t he duration of time over which urine 
samples al"e collected . Linear regression. coefficients were 
determined for log (y-c) on x , as outlined by Snedecor ( 134), 
and the vari ance ratio , F , was deterrdned in order to find 
t he probability that the arrangement of points which de -
termined the curve differed significantly from a straight 
/ 
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line . Since the curves were found to be, in fact, straight 
lines, the values for log (y- c ) and x were replotted, and 
t h e half-lives in the body of chl oramphen:Lcol, its inact .ive 
met8.boli tes, and their sum v1ere read at the point on the 
line represent .ing the time at which 50 per ce n t of the ma-
terial had been exc reted . 
For each subject, the.data for plasma levels were 
p lotted as per cent of the calculated total amount of ma-
teri a l appearing in the total p lasma volume which ' reir.ained 
in the plasma at various time intervals afte11 drug administra-
tion . Th e same c a l culation s as out l ined above ·were used to 
deterrrJ.ne the half-life of chl oramphenicol , its metabolites, 
and theil1 sur1 in the plasma . 
Other liietho c~s of AnaJ.ysi s 
·, 
Spe arman ranlc difference correlation coefficient s , 
chi-s quare ru~alyses, t - tests , determination of Poisson 
dist ribution, semi-interquart:ile ranges,· and l:Lneal1 reg res-
sion analyses were calculated as outlined by Snedec or (134 ). 
The Relative Toxic'ity Index, a ratio ana-log ou s to the 
therapeutic index, was computed for al l drug s as t he r atio 
of the C'""D50 for the drue;.s t o produce t h e5.r res -oective side 
~ .. 
effects in all patients who developed the s:i.de e ffe cts to 
the doses recomrD.ended . by the manufacturers of t he drug ~ and 
a tex t book of pharmacology (122) . 
In addition, f or streptonwcin and dihydr ostrept omycin 
t h e Re l ative Toxicity I ndex was c omputed as the ratio of 
r 
- 13-
the ED50 for the drug to produce ototoxicity :Ln patients 
admini steJ."ed the druzs to t h e l"econrrne nded do s es . 
-14 -
RESULTS 
GEHEH.AL DESCRIPTI ON OF PAr:t'IEli:"TS STTJDIED 
In Table II are l isted certai n charac ter·isti c s of the 
six sample s of pe.t i ents wb.o developed side effects after 
receiving the drugs studied . 
In t hese series, b one marrow depression and ototoxicity 
v'lere mut:ual l y exclusive in patient s treated with streptomy c i n 
(chi - square with p .C:. .. Ol ). 'l'ha t is, no patient VIith one side 
effect was reported to have had the other , b ut the patients 
were not selected in t his respect . Both deafness and ves -
tibular i rnpairment were re ported in many pati e nts recei vin..g 
streptomycin and dihydrostreptomycin, but the combinati on was 
reported more frequently for patients who received stJ:epto-
mycin . Deafness alone was reported more frequent l y for 
patients who recei ved dihydrostreptomycin, and vestibular 
disturbanc e alone for pat ients treated wi th streptomycin .. 
For pat ients who had side effects at tribut ab le to eighth 
c rani8.l n erve damage followin[S treatment with dihydrostrepto-
mycin, deafne ss was re ported six and one-half times raore 
frequently than e quilaboratory change s, while these side 
effects were reported wi t h a pproximately equal fr e quenc y 
for patients treated with streptomycin . Chi - aquare analysis 
revealed that wi th dihydrostreptonrycin deafness was reported 
to occur more frequently t han vestibule.r dysfunction 
( p < .005) and that with streptomycin t he two si de e ffects 
-15 -
occurred eq·ually frequently ( p L • 75). Patients who h ad si de 
effects aft e r treat ment with neomycin wer•e re por te d t o h a ve 
had ac oustic dysfunction, with or without ve st ibul &r dy s -
functi on, b ut n ever ve stib ular• dysfurJction alone . 
Th e ae;e rang e was reported to be about t h e same i n all 
si :;~ drug -treated samples . Tb.e lmver li:tili t was higher fo r 
ne omycin than the rest ) and the uppel' limit fo r trimethad:i.one 
was lower than for the rest . The latter finding mi e;ht b e 
expected since trimethadione is used primarily f'or the 
treatmen.t of petit mal epilepsy in children . 
Th e semi - interquarti le rang es, delineating the middle 
50 per cent of' ae;es of patients wh o devel oped the as s oci8.ted 
side ef fe cts after admi nistration of each drug , indi c ate 
tha t patien ts manifesting bone marrow depression foll owine; 
therapy vv i th chloramphenicol nnd trimethadione, and s trepto -
:w.-ycin to some extent, were re p ort e d t o be younr,;er t h e.n those 
manifesting otot ox:lci ty following tb.erapy with t he strepto-
mycin a nd neomycin . 
More females with tbB side effects were re ported to 
h a ve received chlor~:unphenicol and t r i methadione than nales, 
and r:1.ore males were reported to have received neomycin than 
fer:1ales . The tv1o sexes were reported to have been treated 
with streptomycin and dihydrostreptonrycin equal l y . fre quen tly , 
but t h e pr ep:nderance of cases in which sex was n ot reported 
precludes any definite statement . Bone marrow depression 
was r•e ported more frequent l y for males than ferna.les. 
- 16-
Chi-square analysis of the nuw.b er of males and feroo.le s 
who vrere reported to manifest acoustic or vestibular dys-
function alone s~J.ows no difference ( P< .. 2) in the num:ber of 
each sex who developed either side effect . Either side ef-
feet was re))Ol'ted in fems.les as often. as the oth er• ( p .c . 4 ), 
but deafness ·was reported in males more frequently than 
vestibular disturbance ( p < . 005) . 
In s orre reports of patients recei vints streptomycin and 
neomycin no microbiolog icB.l indication for the use of these 
antibiotics was specifled . For patients receiving chloram.-
phe n icol, not only was no specLfic indication for t h e drug 
mentioned in many case s, 'but 8 per cent of the patients re -
ceived the drug l'or diseases which by them.selves do not 
warrant its use. 
The lower limit for the reported duration of therapy 
was higher for pat ients developing bone marrow depression 
after streptomycin the rap~r than for the other g roups, and 
the upper limit was lower than that for a ll but one of the 
other g roups, the patients vrho received neomycin . The ser.J.i. -
interquarti le ranges of durations of therapy reported were 
similar for all the drug s except n.e omycin, vvhi ch produced 
tox icity after periods of drug. administration less than those 
for which the other a g ents were re portedly g iven • 
. 
All of the patients · l 'h the samples that received strep -
tomycin and dj_hydrostreptomycin were reported to have r·ecei ved 
only one course of these druc; s . A srnall number who Yie re 
-1'7-
reported to have received trimethadione and neomycin re-
ce :Lved more than one course. Three times as m..any pat·ients 
who v1ere treated w.i th chloramphenicol vrere reported to he.ve 
received more than one course as received one course, but 
this ratio may not be the true one, since for another third 
of the patients who received the drus the number of courses 
was not reported . 
The reported patients wbo developed bone marrow s11p-
press.·1.on associated wi th trimethadione and streptomycin 
therapy did so while still receiving the drug . Th is vv-ould 
be expected with t h e patients receiving trimethadione, since 
epllepsy is not cui•able, once and for all , with drug therapy 
in the S8.me sense as is infectious disease. Symptoms of 
ot oto:;d citJ-T in patients who received strerltom:ycin and di -
hydrostreptom:y·cin, and symp toms of bone ma11 row de pression 
in pB.tients who received chloramphenicol· were re porte d to 
have developed from any time during therapy up to s.bout 
six wee~i': s 2.fter cessation of antibiotic therapy . 
No deaths were reported as being due to the side ef-
feet ln patien ts developing ototOJdcity, which is not life-
threaten i ng . rl1he survival rate was about twice as zreat fol1 
the reported patients developing bone marr ov1 to:x:ici ty fol-
l ow·l.ng chloramphenicol and streptomycin therapy as for those 
wb.o received trimethadione therapy . Survival time in t hose 
wb.o died was much g reater for those who had received 
ch l orarnphenicol, and the least for those who received 
trimetl1.2,d:ione and streptom.ycin . 
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None of the reported pa ti en·c s v:rho died did so as the 
resu lt of an acute primary toxic effect of the drug, al-
though such deaths are lmor:rn to occu1.,, for example , 
following chloramphenicol therapy on the newborn. A few 
patients viho received chloramphenic ol reportedly died of 
diseas e s for whi ch they had recej_ved the drug , and most of 
t h e patients who li..ad received chloramphenicol, trimethadione 
and streptonTJcin died of thrombocytopenj_c hemorrhag e sec-
ondary to bone rnarrow depression accord.ing t o the case 
reports . Over a t hi rd of the patients treated with tri-
methadione died of other diseases not i nvo lving b one 
marrow suppress i on, or of diseases wh ich were not reported. 
DISTRI BUTIOlJ OF PATIEJ:TS BY AGE, SEX, SURVIVAL AND FORI\I 
OF TOXICITY 
Table III shows the distribution by a ge, sex and out-
come of their bone marrow depression of t h ose patients whose 
side effects were reported in association with therapy with 
chloramphenicol, trimethadione and streptomycin . Figures 1- 3 
show the frequency distribution by age of these patients . 
Forty-one per cent of patients with chloramphenicol-
induced aplastic anem.ia were in the first decs.de of life, 
anoth er 35 per cent were in the se c ond to four th decades, 
and the remaining 24 per cent l'vere spread over the fifth 
to tenth decades . Sixty-nine per cent of patients with 
trimethadione-induced bone nw.rrow suppression were in the 
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Frequency distribution by age of 78 pa tients with aplastic 
anemia a s s oc i ated with chloramphenicol therapy. 
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depression associated with trimethadione therapy. 
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Frequency distribution by age of 10 patients with bone marrow 
depression associated with streptomycin therapy. 
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Frequency distribution by age of 142 patients with ototoxicity 
associated with streptomycin therapy . 
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Frequency distribution by age of 219 patients with ototoxicity 
associated with dihydrostreptomycin therapy. 
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Frequency distribution by age of 26 patients with ototoxicity 
associated with neomycin therapy . 
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first two decades of life . These findings reflec t the pre -
ponderance of diseases for whicb. the di•ugs are used in 
young er patients. Patients in whom streptomycin-induced 
bone marrow depression was reported were evenly distributed 
over a ll ages . 
l'iiore females were reported to have developed bone marrow 
depression secondary to chloramphenicol and trimethadione 
therapy than male s , while the reverse vms true for patients 
tl1 eated with streptomycin. 11hese data suggest that the sex 
differences are not artifacts of reporting . 
For all three di•ugs more patients were reported to have 
died than recovered, reflecting the difficulty in the treat-
ment of bone marrow suppression .. 
Table IV shmvs the distribution by ae;e, sex , and form 
of ot ot oxi city in the patients complaini ng of or manifesting 
auditory and/or vestibul ar dysfunction associated with 
streptomycin, dihydrostreptoniycin, or neoliDJCin therap~r . 
Figures 4-6 s how the frequency distribution by age of 
these pat ients . 
Reported patients with st11 eptomycin and neomycin-induced 
ototox icity tended to be older than those with dihydrostrep -
tornycin ototoxicity . 
The difference in forms of ototoxicity has been noted 
above, in relation t o Table II . Chi - square analysis re-
vealed no difference b etween t he number of males and 
females who '.'iere re ported to have developed ototoxicity 
as a result of treatment with streptomycin ( p ~ . 5 ), di -
hydrostreptonr,)' cin {p ~ . 5 ), or nemiwcin ( p ...,(_ . 1) . 
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CORRELATIOi'·T OF PERI PHERAL BLOOD DATA V"fiTE DOSE AITD DTJRltTION 
OF THERAPY 
Table V shows the results of rank correlation coef-
ficient calcula t ions for total dose, dose per kilog rB.m, 
daily d ose per ki l og ra...m, and duration of therapy with 
hemog lobin levels, white -cell counts, polymorphonuclear 
leukocyt e differential count s , and p latelet c ounts, for 
patients wi t h bone marrow de p ressi on associated with 
chlore.J.nphenicol, trimethadione , and strept omycin t herapy . 
All reported values concerned with periphera l b lood uere 
ob t ai ned at time of diagnosis . It must b e remembered tha t 
the r2.n!{ correlation coeff icient does not imply a cause and 
e ff ect relationship betv'!een two variables, but it does es -
tlm::: ... te t he 111.2gni tude of t h e degree to wh ich t hey vary 
simultaneously . 
Slnce b one ma rrovv depression, as reflected by lowered 
peripheral blood v a lues, is the lesion that was studied , 
one would expect that any sie;nific s>.nt corre lati ons would 
have a negative sig n, den oting decreasing levels of the 
blood value :r.J.easured wi. t h increasing dose . The on.ly ne.sa -
tive correlations t hat were statistically signi+icant, as 
deterwined by t he t -te st, at a probability leve l of less 
t han . 05, were t h e following , for trimethadi one: total dose 
with heYJ'los lob i n conce ntra ti on a:dd p latele t coun t, dose per 
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kilog rB111 with he1-n.og lobin concentration and platelet count, 
and duration of thera py with platelet c ount. Though it was 
not statistically remarl\:able as measured by the t-test, 
the r e was also f or trimethadi one a negative correla tion 
for duration of therap;y- with hem.og lobin concentrati on. 
There were no statist ically sig nificant correlations, 
for patient s with streptomycin-induced bone m.arrmv de pres -
sion, between dose or durs.tion of therapy and any of t h e 
blood values . Of the c orrelat i on coefficients de t ermined 
for thi s g r oup of pati ents, a l l except those behfeen d o se an. d 
duration of therapy and p l atelet c ount, were negative, sug -
gesting that t h e r e may be some dependence of blood cell 
c ounts on dose and duration of therapy. 
Table V also shows the lack of any correlation b e tw·een 
loss of hearing , in the reported number of decibels lost, 
and dose, in patients with hearing impa].rm.ent secondary to 
treatment witb. strepto:mycin and dihydrostreptomycin. How-
ever, t h ouGh the corre lations were not statistically 
remarkable, they were all positive, as mi g ht be expected 
if the phenomenon were dose- dependent . 
l~· s a more quant itative chec k on the correlation data, 
dose a n d du ration of thers.py were t reated as independent 
VB.riab les and the lab orat or y determinations as de pe n dent 
va ri ables, and linear reg ression coefficients vvere calculate d 
to learn i f the measures of severi t;y- of sig ns did, in fac t , 
de p end on t h e dose and/or duration of t herapy . Again , the 
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slope would be expected to be negative in t hese patients . 
Tb.e results of ·these c omputati ons are listed in Table VI . 
For the re ported p:::t tients with t r i methadi one-induced 
bone marrow de pressi or!, the on ly statistically significant 
neg ative reg ression lines were those for platelet counts on 
total dose . This was , in fact , the on ly one of all the re -
g ression cs.lculations which mat ched a corres pondinG corl'ela-
tion coeff icient, and , as such, suge:;ests that i ncreasing 
doses of tl'imethadione produce predictable platelet le:vels. 
For tl')_e re ported pe.tient s with chloramphenicol-induced 
aplastic anemia, the only statistically significe.nt neg ative 
regression line was that of hemoglobin concentration on 
daily do se per kilogran. The corresponding correlation 
coefficient had the, same s i gn, but was not significant at 
a probability level of less than .05 . 
Positive slopes of the reg ression lines were fo1md for 
white-cell count on total dose in patients with trimethadione-
induced bone marrow depression, and for white- cell and 
plHtelet c otmts on daily dose per kilog ra:u.1 in patients with 
chloramphenicol- induced aplasti c anemia. The slopes of the 
lines had the same signs as their corresponding correlation 
coefficients , thoue;h the values of the latter were not 
statistically significant . 
The reg ression lines discussed above are , in fact , 
straight lines with slopes different from zero, and are not 
constructed on a false assumption of linearity . A line 
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which has a slope significantly diffe r en t from zero, but 
still very small, was found for the regression of hemo~ lobin 
concentration on total dose in patients treate d with chlorarn-
phenicol, but the dispersion of points forming the line was 
found to be the result of the asst1mption of linearity rather 
t han of t he randomness of the distribution of the points . 
In the reported patients treated with strept01:rycin who 
developed b one marrow depress .ion there were no regression 
lines of laboratory r:1easurement s on dose which had slopes 
remarkab ly diffe r ent f rom zero, t h ough none of t he l i nes 
vvere found to result from the assumption of linearit~r rather 
than t h e rando~ distribution of their c omponent determining 
points. These finding s are in accord with t h ose f or the 
correla tion coeffi cients for the same data . The same is 
t rue f or the reg ression of loss of hearing in decibels on 
dose of streptomyc in and dihydrostreptomyc i n , as are the 
s igns of the slopes of these regression lines . 
It would seem that all of t he correlation coeff icients 
and regression .line slopes computed for the data sh ould 
have negative signs if the b lood data reflect a dose -
dependent bone mar>row de press ion . Of the 48 c orrelation 
coeffi cients determined for t h e data, 18 1overe positive, 
and of the 24 regression coeffi cients determined , 12 were 
positive . Of the 18 positive correla tion coeff icients, 5 
were statistica lly significant, and of tb.e 12 positive re -
c; ression coefficients, 4 were statisticall:Jr significant. 
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Of the 24 pairs of corres ponding correlation coeff icients 
and rec ression line slopes for the same data , 1 8 had the 
s ame sic; n; of these 18, ll had neg ative siz ns , but f o r only 
one pail' were both values significant . Reference to tables 
of confidence lLili ts for points j_n the b i n OJ:!.ial distribu-
ti on (118) shows that all the frequencies of positive 
correlation and reg ression coeff'i c .ients r::i s ht be expected 
b~r ch ance alone in 95 per cent of sru::1p les drawn randorll y 
from arrG_ys which are not , in fact , correlat ed , and for 
vrllich significance of correlation between S"Llbsamples of the 
arra~.r s is said to exist , arbit r arily , at the .05 p ' obabi lity 
level . This w_ay indicate that the c orre l ations betweeD dos e 
a nd b l o o d cell levels wh ich were found 1n the present stndy 
are n ot meaning f u l . 
CED50 
Th e medians of the doses and durs..tions of the ir• ad-
ministration of t ~1.e drug s being studied whi ch we r e effective 
in producing the ir• associ a ted side effects in t h e sa:r:1p les 
beinr.:; studied were estirrlB_ted from t~l. e data as outlined pr e -
vi ousl:;r . T~1.e plots of the cum:ul at .ive frequenc:.· in percenta;:;e 
of patients developing the side effect was plotte d as probits 
a .::sainst t h e loc; ari t h:m of t h e d ose . 
Linearity was tested as outlined b y Snedecor (134 ), 
11sin; the varianc e ratio , F . Of 105 plots, 101 Yrere linear 
t b b " l"' 1 , .£> a a pro a l -l~Y eve~ o~ .05 , and the remainin::::; 4 plots 
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'.'J'ere linear at a probability level of . 1 . Each probit tmit 
represents, in effect, one standard deviation of a curve o f 
normal freque n cy distribution , which p lots as a st rai ght 
line . The lineari t ~' of the p lots rnade in t h is study incli:.. 
cates t hat the data of the subg roups represent nor:o1mlly 
distributed populati on s~ and , as such, are homogeneous 
popul ations vrhich can be studied vri th normal Cl.istribution 
statistical methods . 
Subgroups with statistically identical CL!;D50 ' s (or 
C:ST50 1 s) and slope fun ctions (i . e .. , pax>allel slopes), m..ay 
be considered to be subsamples of t he same frequency dis-
tribution of doses or times . 
I t must be remembered throughout the ensuing discussion 
t hat the CED50 1 s and C:2:T50 ' s repi'e sent the medians of the 
doses and pe riods of adndnistration of the dru~ s studied 
whi ch vvere effecti-ve in produc ing t h e si de ef:C'ects in the 
patients ¥rho were selected fox> study oDly if tl1ey manifested 
the side effects . Th e CED50 and CET50 ax>e to b e di ffere n -
tiated fr om t h e ED50 and ET50 to be discus sed later~ the 
me cHan effective dose and time of administration of drugs 
whi ch produced the side eff e c ts in 50 per cent of pe.tients 
t o wh om the drug vvas adninistered . 
Chl oramphenics:>1:_ 
Tab le VII shows the CED50 1 s f or chloraraphenicol wh.ich 
produced aplastic ane nda . 
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There were no significant differences (determined as 
outlined previous l y ) in respe ct of total dose , dose/kg or 
daily dose/kg of ch l orampheni col admi nistered , indicatinG 
that neither sex is moPe sensitive to t he drug than the 
other . Patients aged 0-13 years received a s ignificant ly 
lower total dose than either group of older patient s, but 
in regard to close/kg and daily dose/kg they were not more 
sensitive to chloramphenicol than older pat ients. 
When weight and duration of therapy were t alcen into 
account, it was found that those patients who died had re -
ceived a smaller dose t han those who recovered, and may be 
considered to have b een more sensitive , than t hose who re -
covered , to the toxic effect of the drug on the bone marrow . 
Even though there was no statistically remarka:) le difference 
between these tvvo subgroups of patients in terms of total 
dose , those wh o recovered rece.i ved about twlce as much as 
those wh o died, the same ratio which obtaj_ns in ter1;1s of 
total dose/kg and daily dose/kg . However , most of the pa -
t ients who recovered were reported in two papers (14, 22) 
pub l ished in 1961, in wb.i ch newer and mor•e vigorous methods 
of treatment of t h e si de effect were used . 
The slopes of the lines drawn for each subgroup were 
not different within any g roup of subgroups, except that for 
daj_ l y dose/kg for pat .ients oldel" t h an 30 years , indicating 
that this subg roup cannot be c ompared with the others . 
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Tables VIII and .IX g ive the CED50 1 s of ·crimethacli one 
and streptomycin which pro duced bone marrow depression . 
The total popul ations were too small to permit brea1;;:ing 
t_l.em down into s ubgr•oups :~ bu.t t hes e data wi 11 be discussed 
For patients with ototoxicity associated with stren-
tonrycin therapy (Table X), the CED50 was less for females 
than males in terms of total dose and total dose/kg , but 
more for females in terms of daily dose/leg~ . Ototoxicity 
occurred :l.n patients wb.ose sex was not re ported at almost 
the same total dose as t hat used in males, but the pat5.ents 
in this subg roup were not all reported from one hospital or 
\ 
several hos pitals with predominantly :male popul ations . 
These data sugg est that females were more sensitive to the 
ototoxic effects of streptol'rrycln than mal es in tern1s of 
total dose and total dose/kg . However, tho1.J.gh rn.a les re-
QUired a larg er dose per ki l og ram, the slope of the line 
1Jil 8.S f~reater than that for females, SO that these t'Jyo SUb-
Group s cannot b e compared . Therefore, the data do not 
permit a definitive conclusion as to the relative sensi-
tivity of males and females to t he ototoxic effects of 
streptomycin . 
Patients over 50 years of ag e responded to lower 
total doses and doses/kG than the y oung er a g e Groups . 
Vil1en durat i on of therapy was taken into account with da.i l y 
dose/ kg ., the ol der pat ien ts rece ived more streptomycin t han 
the youne;er ones , t hough this differe nce was not st a tist.ical-
l y remar\ .ab le . There were no diff ere n c es in the slopes of 
the l ines f or any a c; e subg roups . 
Sv.bg r ou p s of pat i ents w'.:~ o developed deafness or ves -
tibular dysfunc tion we :ce stat is t.ical l y d:ifferent in tern s of 
t otal dose and dose/kg , sugges t ing s pecificity of this drt1{; 
fo r t he vestibular appar atus as opp o sed to t he acoustic 
org ans . I n terms of daily dose/ kg , t h e a c oust ic · apparatus 
appear s the rrrore sensitive of t h e t wo . 
Dihydr os trept onry ciJ2 
Th e m.ed.ian e:f f ecti ve total do se of dihyc1rost r eptoxrrycin 
which produ ced ototoxic i ty in patients treated wi th the 
dl'ue; was g reater for males t han femal es (Table XI ) , b ut 
t here 1:vere no s i :;nific ant differences b twee~1. the s exe s ir~. 
ter_ s o f dose/ kg or' dai l y dose/ kg , so t hat no sex spec:Lfici ty 
of t he dru~; can be adduced . Females receive d the s c.me tota l 
dose a s t hose wl10 se sex was not spe cified , but the re \'la s no 
evidence t hat t he l a tter sub g roup might c onsis t l art:; e l y of 
fe males .. 
Patients over 5 0 years ol d with ototoxicity r e c eived 
l ess dihydl"os t r e ptomy cin according to a l l t hree dose 
metameters t han t ho se in the t wo y oung e r age s r ou:)s , but 
the diff eren ce was s tatistically reDmrkab l e onl y i n te r ms of 
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totc..l dose . These data and t he similar C:ata for strepto-
ImJCin, ·yere f ounC"t because of the hig h a 0 e r ange s of the 
patients wi t h streptomy cin- and dihydrostreptomycln- induce d 
ototoxicity . Th erefore , it is perhap s less cert ain that 
dihydrost re pt or::rycin is mo re potent in producing ot ot o:;d c :l ty 
in o l der pati ents than it is for streptomycin . 
Deafness alone o ccu rred with adrillni stration of doses 
of dihydrost re ptomy cin lo1.Yer t han t ho se which pr oduced 
vestibular dys f uncti on alone or a c o1;1b ination o:L both , in 
terns of total dose , dose/kg , and daily dose/kg , t h e re-
vers e of the situa tion found with st r eptomycin . 
Th e s l opes of the lin es for each g ro-:..:tp of dose meta-
me t ers vvere parallel wi t hi n t he limits of t he dat a . 
Ne o~'!:Yc in 
For pat ient s in wh om ototoxicity occurred sec ondary 
to neor.wcin t herapy , as seen in Tab l e XII, t here v;ere no 
difference s i n the median total doses, doses/k[ , or daily 
doses/kg v7h ich were effe ctive in pro ducin g t he s i de effect 
in males and fen~les, or in older and youns er pat ients . 
For pat i ents wi t l1 deafnes s and bo t h ac ou s ti c and vestib ular 
di sturbance there was no diffel~e nce .in terLlS of total dose 
of ne mrrycin adminj ste red . In terms of dose/k? and daily 
dose/kg , the comrJinat i on occurre d after t he ad:·:.li n istra tlon 
of l ower doses , but t he diffe rence was signifi c ant only in 
terr.:J.s of dos e per Ulli t weigh t . Th ese data sugzest the pos -
sibility that t h e comb ination of tar;:_~ e t orc;ans my be more 
3ea sitive t o neor:IJ- ci ~l. t han t h e auditory apparatus 
alone . 
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Th e slopes of the lines f or the subg ro p s were para l-
l el , except those for :.-na l es and patients with deafness alone 
in terms of dai ly dose/ks 1.vere steeper than tLose for their 
associated sub.,. roups , s o t hat the pairs of subg roup s c annot 
be c ompared , and may acc ount for the lac k of sie:;nificance 
of t~e di ffere n ce between the CED50 1 s in dai 13' dose/l[s a d -
r,li n istered t o patients with deafne ss £!. l one and t h ose v1ith 
t h e c o~ )inati on of side effe c ts . 
Comparis_on of CED5 0 1 s fo:c> al l Drug s 
Table XIII is an abstract of CED50 1 s f or t he s i x 
samp l es of patients with druz -induced side effec ts w:t:li ch 
were s tudied . They we re c o~~ared wi t h each other as out -
li n ed .LOr c ompari s on of t_J.e CED50 1 s foi' t he sube r oups . 
St re ptomycin and d1.hydrostrept omycin were e qually 
potent i n producing ototoxi city , in tei'ms of dos e/ kg aEd 
dai l J u ose/ k r; . In te rms of t ot a l dose/l-eg , s t ra pt omyc i n 
v1as five t .i mes a s potent a s streptomy c in in producing ve s -
t:~_b ·ular dysfunct ion a l one ; strept orn:y cin produc ed t h i s side 
eff ect nt one-ninth t h e total do se of dihydrostre p toeyc'ln 
recp..1.ired ; in respect of dai l y dose/l{e; , st rept om · cin was 
half as potent as dihydrostreptmmJcin . I n te:t'Y.1S of total 
dose/kg , dihu-drostre ptomycin was fi ve time s a s pot ent a s 
strept onry-cin in pro duc ins deafne ss a l one; this side effe ct 
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occurred wi t h t l!.e admini st rat:i.. on of dihydrost reptomy c i n in 
one - fifth t he t otal dose of streptonry cin re quire d ; in re-
spect of' daily dose/kc; , dihydrostrept om:ycin was one-third 
as pot ent as stre ptomycin . Thus , the relations b etween the 
dos e metameters and side effects 1nanifested for t h e one 
drug are the opposite t ho se f or the other drug . The p o-
tencies of the two agents "ln producinG the combination of 
side effects co u ld n ot be c ompared because suf f icient dat a 
vrere l a ckinr, . Neomycin was more poten t than either of the 
sti•eptomycins i n producing deafn ess a lone or the c ombi n a tion 
of t h e two forms of ototoxicity, in terms of dose/ks and 
daily dose/kg . 
CET50 
Tables XIV and XV s h ow -t h e CET50 1 s, or t h e medians of 
the ti mes of ad111inistration of the drug s to patients who 
rnanifested the si de effects which were effective in pro -
ducing t he side eff ects . Of 35 p lots, all but one were 
linear at a p robabl lity level of . 05, and the remainlng 
one v:ras linear a t a probability l evel of . 01 . 
Chloramohenicol 
};Iales i n whom chloramphenicol-induced apla stic anemla 
occurred rec eived the drug for a significantly shorte r time 
than females . Patien ts less t h an 13 years old received 
ch loramphenicol f or a sio:ni fic antly s __ OI'ter period of time 
than either o f t h e two older a g e g r oups . There were n o 
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statistically significant differences in CET50 b etween the 
patients who died and those who recovered . The slopes of 
the lines for all subg rou.ps \Yere parallel . 
Despite the difference in CE'l'50' s for the two sexes , 
in terms of the CED50 1 s measured i n all three dose meta-
me ters there was no difference in sensitivity between the 
sexes . The patients 'Nh o died rece .i ved sn1aller doses of 
chloramphenicol in terms of tot a l dose/ke; and daily 
dose/kg than those who recovere d . That they received the 
smaller dose over a not significantly greater period of 
tiHe rni ght sug:~ e st that those who died were, in fact , more 
sensitive to the drug , bu.t even if the difference in CET50 1 s 
is not signifi ce.nt it is sti 11 lal~ge , indicating that per-
haps t h ose who died were not more sensitive . 
The CE'l:'50 1 s for trimethadlone- and streptomycin-induced 
bone marrow depression will be discussed later . 
Streptom.V<:Jin 
Streptor.TIJCin- induced ototox.icity occurred in females 
after admini s tration of the drug f or only one-sixth the 
t .i me required to produce t he side effect in males . Patients 
under 30 years old with ototoxicity received streptor.:ry cin 
f or ten times as lonG; as those over 50> and those from 31 to 
50 years old received the drug for three times as lon[; , sur:~ ­
p; estinc that ototox:i.c.i ty occurs with shorter pe riods of 
administration of streptomycin with advancine a g e. 
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Those patients r.r~·1 . ose to.xi c manife st a tion s were li:L~i ted 
to deafness received s t reptomyc i n for 45 time s as l ong as 
those wi t h vestib ular dysfnnct ion alone. This l!"lay be an 
a rtif a c t ual ob servation reflecting the g reater likel i hood 
of a pat ient to notice ve stibular syJ.11ptoms before di n inished 
8JJ.ditory acui ty while on drug t herapy . 'I'herefore., patients 
who exhibit both form.s of ototo.:~ici t y toc! ether mi ght be ex-
pected to have b een treated for a period of time similar to 
th~:r.t used in patients exJ.1.:Lbi ting the more n oticeable side 
effect . Th e slopes of t he lines of the data for e a ch sub -
? r oup were a ll parallel . 
Refe ren ce to Table X shows t hat fema l es received 
s m2,11er total doses/ks ovor a shorter period of time than 
me.les, but in terms of dai l :y dose / kg the males were more 
sensitive, so tha t it appears t hat neither sex is more 
sensi t ive t han the other to the ot otoxic effects of strep-
tomy cin . Pat l ent s over 50 y ears old received s maller 
do s es/kg over a shorter perlod of time than the y ou ng er 
pat ier ts, which suggests that perhaps older patient s are 
more sensitive to the dl' ug , t h oug b. o l der p atien·i.:;s rec eived 
dai l~· doses/kg n ot unlike t h ose of the youn.ge :r patients . 
Pa.tient s with streptomycin-induced vestibul ar functi on 
a l on e r.1anife:sted the side effect afte r a l ov1er total 
doro:e/k.s and sh orter pe riod of adninistration than those 
with deafness alone , but again , in te rms of dai l y dose/kg 
t h ey we1•e not :cnore sensitive than the latter sub.g r ou ) • 
Di hydro s t 1~ p ~ omy c i n 
The CE'l'50 for dihyd.rostre:9t01!1yc:tn in patients with 
ototoxicity was thl1 ee times as e:; reat fol1 males as for 
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fe males, and t __ irteen t :Lrnes as g reat o..s for those patients 
whose sex was not reporte d . The difference of those pa -
t5.ents whose sex 'IVa s not re_Jorted is so remarkably r rc B. t as 
to sug;'2:est that they are part of an entirely cli f feren.t popu -
l at i on in sorr1e ll.nlmmr-m res pect . Th e patients over 50 years 
o l d received dihydrostre ptomycin for a s h orter period of 
time than those in the t wo youn,::;;e_' age c; roups , t ho· rrh the 
di f .L eren.ce was not statisti c a lly meaning ful . Deafnes s 
alone occurred at a CET50 equal to about one - sixth that 
requi red to produce vestibul ar dysf\mction , and about one -
half the time required to produce s i de effects together . 
The duration of therapy ~:vi th dihydrostreptomycin wh ich pro-
duc ed both audit or y a nd vestibular dysfunction together vvas 
closer to the time required to produce deafness a l one than 
to that required to produce vestibul ar symptoms al one , con-
tra r y to the expectation di s cus seC. previously , but indi c a tine; 
that dihydros t rel! tomy c in attacks t he audit or y appara tv.s nore 
quic l>:: ly than the vestibul ar apparatus . 
The s lope s of t h e li nes in each g r oup were not sta-
tisti cally differen t . 
Table XI sJJ.ows that, as was true for patient s exhibit-
inQ; streptoTI!'j c in-induced ototoxi c ity , fema l es re c eived 
smal ler tot G.l doses/l.i::~ , and over s h orter periods of time , 
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t han males, but in terms of daily dose/ks_: the males were 
more sensitive, so that it cannot be said that ei the i' sex 
j_s c1efini tely mo.re sensitive than the othel' to the ototox ic 
side effects of dihydrostreptomycin~ 
Patients .in the oldest ag e g roup , that over 50 year s 
old, were more sensitive .in respect of total dose/kp and 
daily dose/kg , and they received dihydrostrept o:my cin for 
s hort e r perio ds of t in~e, than the younger patients, but the 
differences were not statistically significant, so that one 
cannot conclude tha t older patients are more sensitive than 
youn,:se r ones to the ototox ic effects of the drug . Deafness 
alone occurred at a CED50 of dihydrostreptomycin, in ter1:1s 
of total dose/ kg, lower than that at which vestibula r dy s-
function alone occurred , and a fter 8. sho rter period of drug 
a dmj_nistration, but in terms of daily dose/kg the two target 
org ans appe a red to be equally sensitive to the drug . Th is 
finding is similar to that for the specificity of strepto-
mycin for the vestibular Ol~gans. 
Neomycin 
Ototoxicity occurred following sho:r't eJ:' perio ds of dru g 
admi ni stra t ion of neomy cin in females than male s , as was 
found f or the stl~e ptmrycins . Th ere were no signi fic a nt 
differences in the periods of drug ad:rr..inistration to younger 
and older patients, or to those who developed deafness 
alone and those with both acous tic and vestibular impair-
ment . Th e slopes for a ll these pairs of data we re :oarallel. 
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Reference to Table XI I shows that, though fe males re-
ceived neomycin for a shorter• time than ro.ales, neither sex 
was more sensitive in terms of total dose/kg or daily 
dose/k£; . There were no 6ifferen ces between the CED50's at 
any of the three dose metameters in respect of a g e, and 
there was no difference in CET50 1 s in respect of a g e . Both 
acoustic and vestibula r dysfunct:lon occurr e d toc ether at a 
lower total dose/kg than did deafness alone, and there was 
no difference in the periods of administration of t h ese 
doses . 
Comparison of CET50 1 s for all prugs 
Table XVI in an abstract of the CET50 1 s tabulG.ted in 
Tables XIV and XV . The values were compared as outlined 
previously . 
Done marrow depression occurred after periods of 
streptomycin administration which were twice tho s e of 
chloramphenicol, and after periods of trimethadione ad-
ministration three times those of chloramphenicol. 
Sinila rly , chloramphenicol was found to be the most po-
ten t of the three agents in producing b one marrow depression 
i:n terns of total dose/kc; and daily dose/kg (see 
Table XI II ). 
Ototoxicity occurl~ e d after· periods of streptomycin a nd 
dihydrostreptomycin admihistration which were not unlike, 
and neomy cin produced the side effecter after one-third the 
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period required by the streptomycins. Ferooles with oto-
tcxici ty received all three ototoxic drug s for shol"'ter 
periods of time than males. Vestibular dysfunction occurred 
after a shorter period of adr~nistration with strepto1~cin 
than dihydrostreptomycin, while the reverse was found for 
deafness following the adrnini strat ion of the two drugs . 
Th e same rels.tionships ·were found in terms of t he CED50' s 
or rela tive potenc5_es of the ototoxic a,~:ents i n respect of 
total dose/kc; . 
ED50 and ET50 
The med:~n doses of streptomycin and dihydrostrepto~wcin 
which were effective in producing a coustic or vestibular 
disturbance in 50 per cent of the patients in tl1.e samp les 
to whom the two drugs were admi n istered al"'e tabulated in 
Table XVII. These data, based not on cunn..1ls.ti ve frequency 
curve s but on plots of the percentage of responders at each 
dose level, are tabulated as the ED50's. The chi - square 
method of Litchfield and Hlcoxon (130) for testing the 
homog eneity of the data, i . e ., the g oodness of fit of the 
line, showed that the data in all 12 plots are not signifi-
cantly heterogenem . .1.s at a probability level of . 05 . 
It requil"ed six times as much streptonwcin to produce 
deafn ess as vestibular dysfunction in terms of total dose , 
and twice as much in terms of daily dose . The differences 
in ED50 expressed as total dose were less marked for 
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dihydrostreptonrycin, of which not quite twice as much was 
required to produce vestibule.r impairment as deafness. The 
difference in daily dose of dihydrostreptomycin wa.s s mall, 
but statistically significant, with slightl~r rnore dihy dro-
strepton:rycin being required to produce vestibular• dysfun ction 
t h an cl.eafnes s . 
To produce deafness, five times as much strept om:y cin as 
dihydrostreptomy cin was required in terms of total dose; the 
two drl..lg s p roduced the same effect in s·l milar but stat isti -
cally different da ily doses .. Vestibular i mpairment occurr ed 
in b oth total doses and daily doses of streptomyctn wh ich 
were half those of dihydr•ostreptomycin . These data sugsest 
that total dose is relatively mo1~e impol~tant t han the daily 
dose in deter:mining whether 50 per cent of the populati on 
·will develop ototoxtcity, and raise the possibtlity t h at the 
differences in total doses of streptomycin and dihydrostrep-
tomycin which p roduced ototoxicity .in the samples of 
ototoxic patients (see Tables X and XI ) may reflect t h e 
relative potencies of the drug s for the two targ et org a n s, 
even though no account is talcen of body weight or dura tion 
of ad:ministre.tion . 
Th e slopes of the lines determining the ED50 1 s vrere 
parallel for all four pairs of subg roups, except that for 
total dose of streptomycin was less steep than the others, 
so that it is n ot compa rable with them. 
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As seen in Tab l e XVI II , the relationships between the 
CED50 1 s and ED50 1 s are roughl y the same for streptor.rycin 
and dihydrostreptomyc in in terms of total dose . The CED50 
(total dose ) for streptomycin to produce de afness was 8 
t .imes that for ve st ibular dis t urbance, whi l e the ED50 
(total dose ) for stl~ept or:ry c in t o p:roduc e deafness was 6 
times that for the other side e f fect . The CED50 (total 
dose) for dihydrostrept o:my- c in to p:r:oduce equilibi•atory 
synptorr:s was 6 times that for deafness , and the ED50 (total 
do se) for the same dl,ug to produce ves t ibul ar changes was 
twice that requii'ed for deafness . This suggests that se -
lectivity for one of two s i de effe c ts is measurable by 
using either type of population sample, since the patients 
from whose data the CED50 1 s wel"e c alcul ated have been 
selected out of a population which corresponds to that 
used to calculate the ED50 1 s . 
l!vhen t he CED50 and ED5 0 a re c om.pared for each drug and 
t oxic nani f estation , the ED50 1 s are l arger than the CED50 1 s . 
'l1he ratio ,D50 to CED50 we_s 6 for stre ptornyc in- and dihydro-
streptomycin- induced deafness , 9 for s treptomycin- induc ed 
vestibular dysfunction , and 2 for dihydrostreptomyc-Ln-induced 
vestibul ar disturbance . The CED50 1 s are s maller than the 
ED50 1 s, but the CED50 1 s fall within the rang e of mi nus one 
standard deviation of the EI60, so that it can be said that 
althous h the doses represented by the CED50 1 s tended to b e 
low, the patients to whom thoy were ach:"J.inistered vrere of the 
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same g eneral population as that from which the ED50 ' s were 
cornputed . This constitutes further evidence for the pos-
sib ility of extrapolating from experimentally determineo. 
CED50 1 s to ED50 1 s . 
Th e ET50 for the entil~e popul ation to whom strepto-
rr.wcin was a dministered was three times as larg e for de a fness 
a s for equilibrium disturbance, while it was ali!lost twice 
as larg e for the latter as the former in patients receiving 
dihy drostreptom:_)rcin. Wh en these values are compa red with 
t h o s e f o r t he CET50 1 s , the ratio of the CET50' s for stre p-
tomy cin- induced deafness to vestibular dysfunction. was 46, 
and the ratio of CE'l'50 1 s for dihydrostreptomycin-induced 
deafness to vestibular dysf1..mction was 6. Thus, t he d if.:. 
ferences between t h e CET50 and E~:so are w.arJ,;::ed when the 
relative durations of administration of the drue; s a re com-
pared for the types of side effects . The CET50 a n d ET50 a re 
much less remarkabl;y different for each drug and type of 
side effect than are the CED50 and ED50, and it cannot be 
ascertained whether the patients who developed the side 
effects f e ll within the rang e of t h e ET50 1 s for the s amp les 
to wh om streptomy cin and dihydrostreptomycin v1ere g iven. 
The CED50 1 s and CE'l'50 1 s for tb.e patients in whom oc -
cul~red ototoxicity associated with streptomycin or 
dihydrostreptomycin therapy were read off the lines used 
to calculate t b.e corresponding ED50 1 s and ET50 1 s for the 
samples of p2.tients to whom the drug s were administered 
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e.nd in some of whom the side effect occurred. These values 
are tabulated in Table XVIII as the ;'bED and 1~ET of entire 
populations receiving the drug which the CED50's and CET50's 
represent . 
Except in reg ard to streptomycin-induced deafness, the 
CED50 1 s and t h eir corresponding CET50's were less t han the 
ED20 1 s and ET4 0 1 s, r es pectively, i ndicating tha t the patients 
selected because t h ey manifested ototoxicity due to t he t wo 
strepto~rcins received sm~ller doses and for sh orter per iods 
of time t h an those wh ich would be expected to produce tl~e 
side effect i n 50 per cen t of the population . 
Compar ison vvith Other Species 
Precisely comparab le data for t he determination of the 
CED50 or ED50 of streptomycin or its dihy dro derivative for 
the producti on of ototox icity in other s pe cies are l a cking . 
However , studie s on cats (119, 124) permit t he very l~oue;h 
estimation of ED50 1 s for acoustic dy sfun ction i n that specie s 
at a t ote..l dose of less than 32 g of st rept o:nwcin an. d. a 
daily dose of less t han 200 ffi0' /1-g:  _ .. !.,.0 of' stre ptomycin , a n d of 
ED50 Is for vestibul ar dy sfun.cti on at a total dose of less 
t h an 6 g and a daily dose of le ss t han 50 me;/ kz . For di -
hydrostreptomycin-induced vestibular dy sf1..mcti on in cats, 
t h e ED50 is less than 12 g total dose and less than 
100 mg/ kg/day . These studies shovr, therefore, that :l n the 
cat, as in the present study of human patients , the 
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ves·ti!Jula~~ apparatus is n~ore sensitive to streptomycin than 
is the acoustic apparatus, and that the ves tibular apparatus 
is nore sensit i ve to streptonwcin than to dihydrostrepto -
mycin . The cat is more sensitive than man to either drug, 
in terms of both dai l y dose/k~ and total dose . 
RELATI"VE TOXICrl'Y IPDICES (RTI) 
The Re lative Toxicity Index (E'l'I) for each drug and 
side effect vras computed for dai l y dose and total dose of 
each drug as the ratio of the CED5 0 or ED50 to the clinically 
rec ornrnended dose . 
The RTI 1 s, calculate d on the bases of the CED50 and 
CET50, and of t he ED50 and ET50, are les s than 1.0, except 
t hose for neo:uzycin . Althoush t h ese indices are analo1:_:: ous 
to t he therapeutic indi ces, t hey are not ca lculated as the 
ratio of the dose requi red to produce a g iven s i de effect 
(e . G ~, deat h ) in 50 per c ent of a popul a ti on , to the thera -
peutic dose in 50 per cent of t:i.1.e population, in vJhich case 
h i gh values are mo re desirab le. Ours is an arti ficial sys -
tem, but one vrh i ch permits comparison of the drugs and sj_de 
e ffects studied . 
In Table XIX are tabula ted: t he doses of chlor amphen5_ -
col, tr.imeth adione, st r e ptonwcin , dihydrostrepto:rrry-cin, and 
neomycin recorm11ended by the i r manufacturers and by a text 
of pharmacology (122 ); the median s o f t he doses of these 
drus s a n d the medians of t h e periods of their administra tion 
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which were effective in prodtlCing the associated side ef-
fects i n the patients selected b ecaus e theJr man i fested the 
side effects (CED50 1 s and CET50 1 s); the ED50's and ET50's 
of streptom,:rcin and dihydrostreptomycin which produced 
ototoxicity in 50 per cent of patients to whom the t ;,v o drug s 
were admini stered; and the R'l'I 1 s of' the drug s. 
For chloramphenicol the RIT for the total dos e 1vas 
five times as l arg e as t h at for the daily dose. The RT I 
for the daily dose of chlormapheni col is t h e s malles t of 
all those whi oh were calculated, suggesting that chloram-
phenic ol was the most e f fec tive in producing its s ide e ffec t , 
in terms of daily dose , of the five drugs studied, in pa-
tients selected be cause they man i feste d s .i de effects. This 
finding i s compatible wi th the finding · that the CED50 for 
all thre e dose metamete rs is l ess f' or chlor·a mphenicol than 
for trimethadi one, s treptorrryc in, and dihyrostrept or:-ry c.in in 
the p roduction of their respective side effects . 
The R1l1I shows that chloramphenicol, in terms of daily 
dose, had 6 times the relative to:xi.city for the bone :rnar-
row as trimethadione, and 5 times t he relative toxicity fo r 
the bone marrow a s streptomycin . It had 4 times t h e re la-
tive toxicity as stre pton~cin in terms of t otal dose. 
Dihydrostreptomycin had twice the ototoxicity of st rep-
tonrycin in terms of t h e RT I based on daily dose, but the two 
drugs were not dissimilar in terms of total dose . These 
finding s are consonant with those for t he CED50 1 s. For 
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streptorny-c .in , t he lo·wer RTI was found for t he total dose 
for ve stibul ar dysfunction , a n d for dihydrostrept omycin, 
for deafness ~ These finding s parallel t hose for t he Cii:D50 
and CET50, suggesting t hat st reptomy ci n is relatively more 
to:;~ic for the vestibular n erve and dihydrostreptormJcin for 
the audi tory nerve . '11he smne relationships do not hold fo r 
t he RTI in terms of daily dose , indicating the relatively 
sreater i mportanc e of the tot a l dose adn inistered, and , 
t herefore , the leng t h of time over whi ch the drug was e; i ven , 
than of the da ily do se ; t h is hyp othes i s is corrobora ted ~J r 
the CED50 and CET50 data for t he pat i ents in whom the side 
effects occurred . Th e RTI ' s based on t h e BD50 1 s followed a 
sJ:nilar pe.ttern in relatj_ on to each othe r in terms of total 
dose . With only exception these RrL'I' s were g reater t h an 
t h ose calculated from t he CED50 ' s, because t h e CED50 1 s are 
l ovrer than the ED5 0 ' s sin ce they are calculated from pa-
tients at the bottom end of t h e dose-effect curve used to 
deternine the ED5 0 . 
The RT I 1 s for bot h the tot a l dose ano. daily dose of 
neomycin are the highes t of t hos e for a ll the dru; s, t h ou.s_j h 
its CI!;D5 0 is simi l a r to that for chloi'arEphe ni col . Th is 
mie; ht sue;.3est that neomycin ·was rela tively less toxic t han 
t h e other drug s i n patient s L_anifest i n g toxicity, but this 
cannot be true si n ce its CED50 was les s than t hat for the 
other drus s. Otherwise, t he Re l a tive Toxicity I :c.de:;c as 
calculated in t h is study a ppears t o be a useful t ool wb.ich, 
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if int e rpret ed properly in t h e light of other finding s, can 
corroborate other data. 
I'> I OTR.A.NSFOF?.l·::A'I'I ON AHD EXCRETION OF CELORA1'•1PHE1TI COL 
Table XX shows the rates of l oss of chloramphenicol, 
its mic orb.iolog icall;y- inactive metabolites, and total nitro 
compounds, fl"om the body i nto the urine, ex pressed as the 
half-life of the antibioti c and ita metabol.ites in the body . 
Table XXI shows the rates of disappearance of t he same 
chemicals fr'om the blood , expressed as their half-11 ves in 
the plasma . The legends for t he tables describe the sources 
of the d£>,ta and the numb ers which are tabulated. Table XXII 
is a composite surmnary of the previous two tables, sho'Ning 
the mean rates of excretion in the urine and disappearance 
from the plaS111B. of chlorampheni col, its metabolites, and 
the su:m of the two, total nitro compounds. 
That the greatest pal~t of a dose can be recovered is 
indicated by the small c-values, wb.ich have been discussed 
previously . 
Chloramphenicol, its metabolites, and total nitro cor.1-
pounds were excreted from the body at about the same rates, 
defined in terms of percentage, of the total amount ulti-
I18.tely recovered, pe r hour, and not in terms of absolute 
values per hour . The three chemi cals also disappeared from 
the p lasma at about the same rates , sL:ularly defined . 
However , the rates of their disappearance from the plasma 
were two to three times g reater t han their rates of ex-
c re tion in the urine . 
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The hal f-lives found i n these calculat ions were not 
remarkab l y different, by the t-test, from those obt ained 
experimentally by others ( 127) foi' the half-life of tot a l 
nitro comp oun ds and microb iolog ically a ct.ive cb.lorampheni col, 
of 4 . 8+0 . 14 hours and 2.7~0 . 75 houl~s, respectively , even 
though these previ ously reported values are about twice 
t h ose obtai ned in the present study. 
Table XXIII-A s how s the manimum amounts and the ti me 
r eqv.ired to reach t ho se a mounts, of chlorrunpherlicol, its 
microbloloe;ically inactive metabolites , and total nit ro 
c or0.p ounds whi ch can be e xpe cted to a ccu:!:nulate in the b ody 
1.n1 i th hypothe tic al repeated six-ho1uly doses of 12 . 5 mg/kg/ 
day ( equivalent to a total daily dose of 50 me;/ kg) admin-
istere d to a 70 - kg human subject. This dose c orresponds t o 
an acceptable therapeutic regimen as described by the manu-
factu.rer and by a text of pharmacology ( 122) . The 
computations are based on the half -lives of the three chemi -
cals in the b ody, as determined from urine levels of the 
colilpounds, and so estimate t h e amounts of t hes e compoun ds 
present in the vrhole body and not in the plasma alone . Th e 
amounts of chlora:.m.phenicol, its metabolites, and total 
nitro comp ounds v1hich re main in the b ody 24 hm.1rs after the 
adr.~ni st ration of a last dose after attai n ing equilibrium 
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between intak e and loss, a t the r:mximum a mount s which can 
accumulate, are also shown . 
Th e maximum amount s expected to accu ..mulate are derived 
f rom the percentag es of the oric; inal dose which are re-
coverable a s the three chemi cals studied . Ni nety per cent 
of an intravenous or oral dose is recoverable in the urine; 
of this a mount, 15 per cent is recoverable as microbia-
loe;i cally a ctive ch loramphen:lcol and 100 per cent as tot a l 
nitro comp ounds , so that 85 per cent is presumed to consist 
of mi crob iolog ically inactive metab olites . Therefore, 
15 per cent of 90 per cent of the orig inal dose wa s con-
s i dere d as the dose of active chlorarnphenicol administered, 
85 per cent of 90 per cent of the orig inal dose was con-
s:lderec1 as the dose of inactive metab olites administel~ed, 
and 100 pe r cent of 90 pe r cent of the original dose was 
considered as the dose of total nitro c ompounds administered . 
These data show t hat al::nost 5 g of tot a l nitro compounds, 
one-seventh of wb. ich is a ctive ch loramphenic ol, will a cc u mu -
late in the b ody with the chroni c administratj_on of a 
clin ic a lly useful dose sche dule of chloramphenicol. There -
f ore, in t h e body , with the administration of t herapeuti c 
reg i men and after eqt.lilibrium between intak e and out put has 
been reached, si x times the amount of nitro compounds of 
unknown pharmacolog ical action is present as of nitro c om-
n o11nds of knovm phar w..aco l or.:: ica l action .. !.. - , _ , 
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I'.Iaximum a mounts of microbiologically active chlo ram-
phenicol are obt a inable in about tvvo-thirds t he time 
reouired for atta.ining maximum amounts of inactive chloram-
pheni col and total nitro compounds . Maximum amot.u:tts of the 
latter are attained after five or six doses, s o that t h is 
tl1.erapeutic reg i men provi des l11EL~imum body level s quickly, 
even if it is usually maintained for ten to fourteen days. 
Tvventy- four ho1.u~s a fter withdrawal from t h is dose 
schedule, only about 3 per cent of each comp ound remains 
in t he body . Within another 24 hours, of cours e , only 
mi nute a mounts of the drug would remain in the body . 
Table X..XIII-B shOV'lS the rt1B.x i nmm ain.ounts and the ti:~11e 
required to reach those a mounts, of chloramphen icol, its 
mic robiolog ically inactive metabolites, and total nitro 
compounds which can be expected to accumulat e in the plamna 
under the same conditions as used to del"i ve the values in 
Table XXIII - A. Th e computations were based on values de-
rived from studies of plasma levels of chloramphenicol and 
.its metabolites, but were otherwise identic a l wlth thos e 
used in Tab l e XXIII-A. 
The values of the maximum obtainable a mount s in the 
p lasma are about t wo-thirds of those tabulated in Table XXIII-A 
for t he total amounts of the compounds .in t h e b ody , while 
the ti me required to reach t h ose levels was ab out the s ame . 
Therefore, it can be estimated that the volume of distribu-
t ion of chloramphenicol and its met abolites is about 
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50 per cent grea tel1 t h an the plasma volume a l one, and it 
appears that, because of this, the levels of the drug in 
the urine are the more useful indices for determining its 
amounts in the body . I t cannot b e said that t he amount s of 
drug o11 its metabolites in the p lasma alone are responsible 
for its toxic effect on the bone marrow . 
Data are available (121 ) indicatinc t hat in the dog , 
chloramphenicol is distributed in the blood and other tis-
sues in a ratio of about 1 to 1, except that the amounts 
in the excretor;sr or g ans (ki dney , liver, bile ) are g reater . 
Our data , derived from studies in humans, stu;c;est a 
ratio of blood to tissue concentrat .ions of about 1 to 1 . 5, 
but th e high c oncentrations in t he excretory org ans may be 
re sponsib le, or there may be a difference between dogs and 
h umans in this regard. 
When de.ta (121) 11 elating maximur1 serum concentrations 
of ch loramphenicol (measured as total nitro c ompounds ) to 
sing le ora l dooes admini stered to hu:man subjects are p lotte d 
(Figure 7), it is apparent that increasing single doses p ro -
duce p r edi c tably :increas i ng serum dx•ug c oncent rati ons . 
S i milar dat a a re no t availab l e for tissue concen t rations 
after sing le doses . 
The ma."'<:.imum obtainable a mount of total nitro c orapounds 
in the b l ood , as de te rmined by plasma levels, with ch r oni c 
administration of chloramphenicol is approx:lmatel:y- 3200 l'!'J8 • 
Assuming that serum is about 3 pe r cent of the t otal body 
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Figure 7 
Maximum serum levels of total nitro compounds obtainable 
following single oral doses of chloramphenicol to human subjects 
(121) . The regression line represents the equation 
Y=l4.3X + 2 . 4 micrograms/milliliter. 
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weight of a 70-kg huroan subj ec t, chronic administration of 
chlol"amphenicol woul d t hen y ield serum con centrations of 
about 1280 mcg/ mle Using the data p lott ed in Figure 7 , it 
is found that it would require a sing le dose of 88 . 64 g to 
yie l d serum concentrati ons of t his magnitude in a 70 - kg 
adu lt human subject, or 1267 TI18/ kg . Th is is 25 times the 
manufacturer's recormnended dose of 50 m:;/ kg , 12 times the 
dose whi ch produc es acute to:;d city in hm112.n neonates (137), 
and 12 times t he LD50 for acute toxicity a fte r an intra-
venous dose , or a l mos t twice the LD50 for a cute toxicity 
afte r an oral dose, in n ice (123). Acute toxi city has not 
been assoc i ated with any hematoloc;ical c hanc es in a n L::mls 
or man ( 12 3 , 13 '7 ) • 
Depending on the size of the incli v i dual dose and t he 
duration of therapy , total amounts of ch loramphenicol a nd 
its metabolites u p to and i n cluding t he maxima t abul ated 
in Tables X..XIII - A and XXIII - B c an be ach i eved . l.Iost of 
the pat i ents selected b ecause they man.ifested toxicity a nd 
studied to compute the CED50 values received tot a l doses 
of chloramphenicol g reater t han a few g r ams. 'I'h e daily 
doses adJ:Yi nistered to t h ese pa tients were sri1all . The t otal 
a ccumul ation of the d r ug in t hese pat ients vms l a r g e , but 
of varvinr<: and unknovm concentrations in the pl a sma and 
u '- · 
t issues . The levels of t h e drug which obtain the se rum. 
following a cli n.ic a lly therapeutic regimen are l arge enough 
to produc e very l arg e ser1J_m, and tis sue, concentrations of 
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the drug , unachi e vable with single doses . Varyine; tissue 
concentrati ons of chloramphenicol and its metabolites, --
corresponding to diff e rent " dose levels 11 vvit h respect to 
hematopoieti c tissue co n centrati ons -- can be achieved 
depending on the dose, durat ion of therapy, and the metabolic 
indi-vidua li ty of t he patient. Therefore , it cannot be said 
t hat the occurrence of aplastic ru1emi a following chloram-
phenicol thei•apy is no t dose-de pe ndent, since two compounds 
are present i n the body f'ollmYing administration of the dru c; , 
only one of vihich h as bee n characterized phar macolos ic ally . 
Comparison v,r i th Trimethadione and Streptortrycin 
Data for similar c a lculati on s for trimethadi one were 
not availab le, but s ome comparable information could be 
derived frolil other sources (116, 1 36 ). Trimethadione is 
completely conve rt ed to 5 ,5-d i meth~•l - 2 , 4 -oxazoli dinedione 
(DIIO) in the dog and man . 'I'his metabolite, t houc h not the 
parent co mpound, can be measured "Ln. t he blood . About one 
da-v is requ ired for the complete demethylation of a dose of 
trj_methadione to m.:o , but t h e metabolite disappear s at a 
r a te of onl y about 6 pe r cent per day . The half-l i fe of 
trimethadione in the blood , then, measured as Dl.IO, is ab out 
200 hours . Fol lowing repeated hypothet:l cal datly doses of 
trimethadione of 30 :mg/ kc (0 . 9 g/day ) admi n istered to a 
30 - kg hurnan chi l d in equal doses ever"J eight h our s, about 
71 g rf::uns of DLO can be expe cte d to addumulate in the blood 
vohurre . This amount is 22 times the a mount of total nitro 
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c omp ou ncl s which accurmlate i n tb.e blood f ollowing chr oni c 
a dminis t r a ti on of chloramphenicol . Since the elimi nati on 
of DiflO i s so nuch slower than that of chloramphenicol, a 
f a r g reater arno"Lmt of DivlO, in both absolute and relative 
quanti ties, remains 24 hours after wi thdrmval from chronic 
adrni n is t ration .. 
Th e half-life of streptorrry cin in the blood or b od"~r 
" . 
c ould not be cal cu l ated from a vailab l e dat a . Two l ab ora-
tories reported half- lives in the b lood of streptonwcin a s 
2 . 4 h ours(l26) and 2 . 72+0 . 47 hours (115), re s pectively. 
Th is rat e of d:is appear a nce of streptom:yc :t n fl1 0 m the b l o od 
is a lit tle g reater than tha t of chlora mphenicol and its 
metab ol it es .. Following a hy pothetical course of once daily 
do ses of 2 . 86 mg/kg (2 .o g/ day ) of streptomycin adm.i n i s ter•ed 
t o a 70 - kg huma n sub ject, only about 160 r.o.g of t h e drug c a n 
b e e xpected to accur!lulate in. the blood volume , based on t h e 
r e por ted half-lives, and onl y ab out 3 rng will remain i n t h e 
b l o o d f ollowing vli thdrawal from chronic admini str·a t ion . 
These amounts are much lesf) than those found in the bo d:;y· 
with chronic administra t i on of chloramphenicol, b ut since 
data a s to leve ls of s t re pto1T.ryc.in in the Ul""'ire were not 
ava ilable, the r e sults may not be comp~::u""'able .. 
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I HFLtmHCE CF l'WEBER OF COURSES OF CHLOEAJ,IPHElTICOL 
Of the seventy -eight patients with aplastj_c anemia 
following chloramphenicol therHpy, fifteen vrere r e p ol~t e d to 
h a ve received continuous t1•eatment with the drug over the 
period of drug administration, and thirty- nine were reported 
to have received intermittent therapy with mo1•e tha n one 
course of the antibiotic . The number of courses was not 
re p orted for the remaining twenty-four• patients . 
In Table XXIV, cases of pancytopenia followir.~ ch loram-
ph enic o l therapy are tabnle.ted by nurrtbers of courses of the 
dl"Uf~ a dministered., for those patients for whom the e x act 
n1E11b ers o f cov.rses were reported. Patients reported to 
man ifest depression of only one or two bloocl. cell elements 
were similarly tabula ted . 
Chi -square evaluation of the tvro g ro,J.ps indicated 
(P <. Ol) rer)Qrted to have depression of only one or tw o cell 
t ypes were more likely to be diag nosed during the first 
c ourse of chloramphenj_col tr•eatment than those vm.o developed 
pancytopenia . Comparison of both gl~oup s vri th theo r etic a l 
c1istributions, constructed so that equal numbers of patients 
f a ll i n each g roup of numbers of cours e s, reveals ch i-squares 
ind.i ca t .ing ( P .(, 01) significant diffel"'ence s between the ob -
::;erved and theoretical frequencies. Therefore, it appears 
that it is not likely that either pancytopenia or depression 
of onl y one or two cell types was equ.ally likely to occur 
du ring one course of chloramph enicol t herapy .. Neither g roup 
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of patients fitted a Poisson distribution, so that it cannot 
be assumed that multiple courses of chloramphenicol are not 
criti ca l to the producti on of aplastic anemia in t ho se pa -
tients who deve l op the side effect .. This is not to say, 
however, that multi ple courses are cr1.tical. 
Table X:X.V show s the re sults of conparing t h e effect of 
continuous a dministrat i on of chloramphenicol with the effect 
of intermittent treatment, with more than one course of the 
drug, on the production of aplastic 8.nemia . The Spearman 
rank difference correlati on coefficients were calcu lated for 
total dose/kg agai n st durat ion of thel'apy for severa l g roups 
of dose schedules, as well as the corresponding linear re-
g ression coefficien ts and the intercepts of the latt er , 
which indicate the basic dose levels used. in the patients 
studied . 
There were significant positive correlat ion and linear 
reg ression coefficien ts for all patient s, treated continu-
ously or intel''Eli ttently for up to 120 days, indicating that 
t otal dose/kg did, in fac t, increase with duration of therapy 
up to a limj_t of four months. No significant corl~elations 
or resression coeffj_ cients were found for patients treated 
intermi ttently for up to 730 days . Sic;nificant pos itive 
correlation and reg ression coefficients, the latter beil'1_g 
of t h e same rnagn.itude, wel~e found for both pat ients who were 
treated continuously for ·up to 180 days , and those wh o were 
treated non-c ontinuousl;T for up to 120 days, su.sge sting 
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that the lattel' group of patients were, in fact, t reated at 
dose schedules not di ssimilar from. the continuously treat ed 
ones . These data suggest a relationship between total 
dose/kg and duration of therapy, for periods of f our to six 
months of chloramphenic ol therapy . Howevel1 , sine e t h e re -
lati ons h i ps of both the total of continuously and 
intermittent l y tre 8.ted pat ients, c.nc t he patients treated 
c ontinuously or intorrr1..i ttently , to the duration of therapy 
was the s arne , one cannot i · ··l~- : c r t e 
cause of bone 111arrow de pr•ession . 
any diffel,ence in the 
Th e basic dose levels used in thes e l as t two g roup s of 
patients, 51.17 and 58 . 48 mg/kg/day, were not dissini.ilar 
fr om t he standard recormnended dose of chloramphenicol, 
50/mg/ kg,/day . 
DISCUSSION 
USEF'ULNESS AND LDITTATIOHS OF THE EETHODS 
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For every unitary biological effect of a drug there 
exists a dose-effect curve relationship of the nature of a 
continuous monotonic function. In any such graphically 
demonstrable relationship, the reactivity of the drug ef-
fect under study can be quantitated in terms of the slope 
and intercept of the line if it is straight . A pharrna-
cological side effect, or any effect of a drug other than 
that for which it is administe red , whether' desirable or 
undesirable, also shows a dose-effect curve . A hypersensi-
tive, or allergic , side effect shows a dose-effect curve; 
.it is difficult to study, but it must show, by definition, 
an antigen-antibody reaction . Idiosnycratic side effects 
a re comp l etely 1.m.pred:i.ctable, and show neither dose - effect 
curves not antig en- antibody reactions because these effects 
have their orig ins in the pati ent himself to whom the drug 
is administered . A side effect may or may not be toxic, 
that is, of sufficient severity that if it i s not reversed 
it may be permanent ly damaging or e ve n fatal . 
Pharrr~oological and hypersensitive effects or side ef-
fects, by virtue of their r esiding i n pr•edictab le properties 
of the drug and not in s ome unfathomab le condition of the 
patient, as is true for the supposedly idi osyncratic side 
effects, ought to be able to be studied by means of normal 
distribut i on statistics .in homogeneous sarn.ples, if the 
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frequency of occurrence of the side effe ct , a unitary b io-
log ical phenomenon, is dis t ributed normally with res pe ct to 
sor;1e function such as dose, do s ac, e , or period of administra -
t ion of the drug w 
The prinmry obje c t ive of this study was to test the 
hypoth esis t hat dat a col lected in r etrosp e c t fro m hetero-
g e neous sources can b e poo led and analyzed systematically 
to y ield meaningful r esult s , as if they were c ollected in 
a prospective experiment wi th a h omog eneous population . In 
order to do so , data from the litera ture were poole d , as 
described , CED50 1 s e.nd CET50 ' s, bas ed on p l ots of the cumu -
lative frequency of side effec ts at various doses and 
per.:i.ods of drug admi nis trat ion for patients selected be cause 
t hey man:lfested t h e side e ffe cts, were determined . These 
data 'Je re f ound to f ollow t h e criteria f or n orTI12.1 dis trib u-
tion statistics, and the sample s of the popula ti ons w·ere 
fm.md to be h omog en eou s . 
It must be rememb ered that these cu rves are not dose -
effect curves . \"men plot ting cumulative per cent frequency 
distributions against dose or time, when 100 per cen t of 
the su jects reacte d t o the drug , t he resultinz, CED50 1 s and 
CET50 t s are n ot the same as t he ED50 1 s and ET50 1 s . In the 
l a t ter case; Cl.E.1Ul Lt i ve frequency curves a 1•e no t used, but 
curve s which were based on the pe rcentag e of individuals vYh o 
reacted a t each dose or time level . Fo r ex:?...L"lp le, the va l ues 
of t he CED50 for patients .in v1hom ototoxicity occui'red 
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following administre.tion of streptomycin and d-Lhydrostrepto-
r,r_ycin were smaller than the values of the ED50 . The ED50 
values obtained by the me thod used are the median effective 
doses for 50 per cent of the population, and the curves 
used to obtain t hese v:::tlues are dose-effect curves. How-
ever, even if the curves used to determine the CED50 and 
CET50 in this study are not dose~effect curves, t hey do 
permit the collection of :meaningful data and results, so 
that useful quantitative description may be rr.ade of the 
reactivity of pat ients and various groups of patients who 
did respond to the drugs . 
The method for determining the CED50 and CET50 fails to 
account for the pat ients in whom none of the side effects 
being studied were, or could be, observed, and vlr.1o make up 
the largest port ion of patients to whom the dl"ugs are given. 
It is this failure which prevents these curves from being 
dose-effect curves . Without dose-effect curves, one cannot 
interpret single points known to lie on a curve, or predict 
according to those points, or relate them to other points . 
Thus, one might cons.ider the curves used to determine the 
CED50 and CET50 for the samples of patients who developed 
the side effects associated with the drugs investigated as 
parts of pharmacological dose-effect curves for total popu-
lations to whom the drugs are adminj_stered, but by no 
rationale can they be considered as whole dose-effect curves 
by themselves .. 
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The CED50 values are not contingent on the constancy of 
dose during any fixed period, as is usual in most dose-effect 
experiments. Therefore, it cs.n be assumed that tho results 
are independent of such a factor, and that the CED provides 
inforrr.ation concerning the Relative Toxicit y Index which is 
similar, if not identical, in definition to the the rapeutic 
inde.::~ , which is derived by testing large numbers of patients 
at each of several dose levels. 
The most important sort of inforlDati on which can be ob-
t a .ined with determination of the CED50 , uslng the cumulative 
frequency curve to deterEline the in.fluence of dose on the 
occurrence of the side effect, is infornmtion relat.ine; to 
relative sensitivity, or relative potency, which are func-
tions of dose . These data can be, and have been here, ·used 
to co:r:1pare the sensi ti vi ty, in terms of the dose required 
to produce a given effect , of various g roups of patients, 
such as males and fenmle s or older or younger patients, or 
patients displaying more than one effect in association 
with one drug . 
As an extension of t b.is way of using the data, it was 
found, when comparing the CED50 and ED50 for streptm:zy-cin 
and dihydrostre ptomycj.n in producing auditory and vestibular 
dysfunction, that eithel1 of these two types of data could 
measure selectivity· of a drug for one effect over one or 
more others, in pat .ients receiving that drug. This mB.~;:es 
it pos,sible to adr:rl. n ister a drug to a sr!mll number of 
' 
' . 
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subjects unti 1 they sh ow one or the other effect eing in-
vestisated a n d to determ5.ne the relative CED50 1 s, in s te a d 
o f t e sting very larg e nunfuers of s~fujects to obtain the 
ED50 1 s . Thus, it a ppears that the ED50 can be predicted 
f rom t h e CED50 , re quirins only a small srunple size, and per-
mitting a retrospective treatment of data rath er t h an 
prospective experiment a tion . 
Severa l possib le errors 2.nd mnissi ons may contrib ute 
to the results obtain ed. Approximately eighty differen.t 
lab oratories and h ospitals are re presented in this c o llec -
tion of data . Th e exact doses administe red and dura ti ons 
of their adn inistration were calcul a ted as closely as p os-
sib le from whatever data were g iven in some cases . The 
omission of the wei3hts of the patients wa s a h indran ce to 
computing t he doses per u n it body weight . The use of 
standa rd ag e - sex--weight tables introduces a random error 
int o the data . Even with this li~~tati on , the data were 
f oun d t o b e homog eneous, probably because the sample size 
was sufficiently large to reduce the influence of this er-
ror on the results . 
More extensive case reporting is necessary f01~ t h e 
adequate analysis of clinical data reg arding drug side ef -
fects . Case reports should include the patient's ag e, sex , 
r a ce; b ody weight, dose of drue; administered, other drug s 
ad:r.U nistered, dur2.tion of drug administration, dosage 
schedule, diac nosis of disease for which the drug was 
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prescribed, leng t h of· side effect manifestations, methods of 
treating the side effect, cause of death, and autopsy find-
ings . Laboratory data should be reported in full, even if 
seemingly unrelate d to the condition under study, since 
retrospective analysis of such data from the literature may 
provide i mport ant clues to various concepts of t h e side 
effects . 
Insufficient peripheral blood laboi'atory dat a before 
adr;linistration of the drug s were reported , precluding analy-
sis of s pecific change s in :lndi vidual patients . These dat a 
are understandably 6if'i'icul t to obtain, but it should be 
useful to perform some routine studies before initiating 
therapy vli th any drug v.rhich one has reasons to believe 
mi g ht a f fect the blood or the blood-forming org ans . Th is 
omi ssi on is particularly i mport ant in view of the assunp-
tion that most patients who received streptomycin or 
chloramphen icol did so as treatment for bacteria l infections 
which presmnably c aused leukopenia or leukocytosis, or even 
anerllia or thrombocytopenia, depending on the micro-organism 
involved . Though an attempt was made to standardize the 
hematolog ical data by anal yz ing on l y those which were ob -
tained when the patients first c omplained of or manifested 
signs of bone marrow depression, this standard was subject 
to the differen t :j udgments of the investigatoi'S r eporting 
the cases . The data obtained in the pre sent study indic ate 
that no significant relationships existed between dose of 
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the drugs responsible for bone marrovr depression and the 
severity of the sj_de effect as measured bjr the hematologi -
cal findings, but in vievJ of the shortcomings of the available 
data this may not have, in fact , been true . Again, it is 
·i mportant, in regar d to the blood data , to note that they 
are not available for all patients receiv.ing the drugs . 
There are probably many patient s who may develop not only 
clini co.l l y undetectab le s i de effects , but al s o man3r whose 
side effects are not diagnosed , are unreported, or are over-
loolced in some othel~ way . 
It has been possible , I1oweve r, to collect both quantal 
data (fo r determining the CED50 and CET50) and quantitative 
data (for determininG the dose-dependence of certain blood 
and audiometric values, and for deter:cnin.ing factors of bio-
transformation and excretion of the druc;s) to ascertain 
certa.in features of some drue;s . The quant i tative data re -
lating to b l ood cells and auditory acuity could not be used 
to draw any meaningful conclusions, but the quantitative 
data pertaining to p lasma and urine levels of the drugs 
could be used profitably . The blood and hearing data do 
shovr, however, that the severity of the side effects was 
not well- related to dose . The CED50 and CET50 data show 
that the occurrence , or non- occnrrence, of the side effects 
were anal yzable as related to dose . 
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COl:1P3U·USQl\! OF RESULTS YIT TH THOSE OF O'l'I-ffiRS 
It ]:l_as been thought ( 11) that females are more sus -
ceptible to chloramphenico l-induced bone r.<12.rrow toxicity 
t han a r e males, p l"esumably because more ferrra l es than r.~Ja1es 
mani fest the s"ide e f fe ct. However, sensitivity propel.., l:v 
relates onl y to do se, and our study shows that the side ef-
fect did not • occur in on e sex at lower or higher doses than 
in the other :, so that it cannot be said that one sex i s more 
sensit ive than th e other. 
The most convincing avail~Jle evidence that the effect 
of chloramphenicol on the bone marl' OW is dose-dependent are 
reports (131, 133) of 22 pat .ients v,rho received the dr•ug for 
bac t erial infec tions . I n two of ten who were administered 
a low dose ( 11-45 m.g;/kg/day f'or 4 to 59 days ) , a qu antita-
tively smaller resp onse was seen in tern s of numb ers of 
v a cuolated erythroblasts, red- cell counts, and reticulo cyte s, 
than in all of the 12 \"Tho recei ved highe~ do ses (40-85 mg/kcJ 
day for 4 to 27 days ). No changes were s e en in the bone 
marrow aspirates of s even normal volunteers who were ad-
m.inist ered the h i gh er do se range. 
A more recent study (132) describes 41 patients, 20 of 
whom. YJ'ere administel"ed 2 g of chloramph eni col (20-47 mg;/kg ) 
for 7 to 21 days , and 21 of whom received 6 g ('75-144 m,g/ ke; ) 
per day . S :Lgns of hena tological t o:x:ici ty were found seven 
days after the initiation of treatment in tvro of t he twenty 
who received the low dose range . Seventeen of the patients 
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who I'e cei ved the higher dose rang e developed vacuolization 
of erythroblasts, anemia, and thrombocytopenia; one pat ie nt 
showed leukopenia . In both groups , pronpt recovery followed 
withdrawal of' chloramphenicol therapy. 
It has been suggest ed (21, 24) that intermitten t or 
interrupted therapy with chloramphenicol, as opposed to its 
continuous adroini st rat ion, may be etiologic in the pe.. tho-
genesis of the aplastic a..n.emia produced by the drug. In 
our study no difference between these two fox•ms of therapy 
was found in the relationship of dose/kg to duration of 
therapy, sugge sting that one is not causally relat ed to the 
p roduction of the side effect any more than the other . 
It is thought that the results reported here provide 
the first quantitative confirmation, in terms of sensitivity 
measured by dose, of the known relative sensitivity of the 
vestibular apparatus to st rept omycin and of the auditory ap-
paratus to dihydrostreptomycin (72, 122) . It was t :i.l.is 
relative s pecificity of the two a g ents for the two targ et 
organs 1Nhich led to the removal of dihydrostre ptomycin fr om 
the ax•mamentariun for tbe treatment of tuberculosis, since 
it was thought that vestibular dysfunction, which is re-
versible, or can be compensated, would be a less disturbing 
side eff ect than deafness, which usually is prog ressive a..n.d 
irreversible (72). 
As was found b3r othe:r.1 s (88), no relation could be found 
between dose of st rept orPJcin adm.ini st ered and the severity of 
audi to i'JT i mpa.irLlent . 
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A previous study (86) has suggested that t h e severity 
of vestibular symptoms was greater in older patients . 
Another report (101) found that the percentage of patients 
at different age levels who developed auditory d~rsfunction 
after a relatively constant total dose of streptomycin in-
creased with age. Our study reveals CED50's in terms of 
total dose and total dose/kg vv-hich support these previous 
finding s, but precisely comparable data are lacking . 
Anotb.er study ( 92) has presented evidence that the in-
cidence of occurrence of streptomycin-induced ototoxicity 
decreases with decreasing daily dose and total dose of the 
drug . This is confirmed by the finding of a dose-effect 
curve in the studies reported here, from which the ED50 1 s 
we~ee calculated . 
I'.10HJ3IDITY Rl\.TES OF 'l'I-IE .S I DE EFFEC~rS 
Table XXVI shovrs the morbidity rates for• t h ose diseases 
for which the drug s included in this study are the treatments 
of choice, as well as the morbidj_ty rates for the side ef-
fects associated vrith those drugs. The morbidity rate for 
chloramphenicol-induced aplastic anemia is not greatly dif-
ferent from those for two diseases for which it is the drug 
of choi ce, and it is more than t wi ce that for a third such 
d.isea.se. However, chloramphenicol-induced aplastic anenia 
has the lowest morbidity rate of a ll the drug-induced side 
effects studied here . 
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Blood dyscrasias occul' much more frequently with the 
use of trimethadi one and the strepto:nzy- cins than with chloram-
phe ni col . Neutropeni a appears to occtn' with alarming 
frequen cy .in pat ients t reated with trimethadione, but death 
secondai'Y to tri1:1ethadione-induced a g ranulocy tosis is rar e .. 
In Table XXVI are also tabulate d the percentag e of a 
sel'•ies of 1622 ca ses of drug - induced bone marrow depression 
caused by e a ch drug included in the present stuqy . Even 
though there is a low morbidity rate, among the populat ion 
at risk, for chloramphenicol-induced bone marr ow suppression, 
the drug was resp onsib le for almost one qua11 ter of al l t he 
c ases of drug -induced b one r!1ar row depression reported . 
St reptomycin was the next most frequently incrir:linated drt1g . 
The mol'bidity rates of the side effects associated with 
streptonzy-cin and di_hydrostreptomycln are many fold the :mor-
bidity rates for the disease for which the drug s are most 
frequen tly used, tuberculos5. s . Deafness associated with 
these two a gents occurs abou t 4500 times as frequently a s 
deafne ss :mi ght be expected to occur i n pat ients with tubercu-
los is, who make up the population at risk for streptomy-c in-
induce d side effects, and even occur twice as frequent ly a s 
deaf ness in t h e t otal United States population. 
Th e mol"bidi t y rates :for vestibular dysfunction in pa-
tients tre ated with b oth streptonrycin and dihydr ostreptoTizy-ci n 
are :r•oughly one - half those found for deafness. However , 
morb:ldity rates do not show the sele c tive t oxicity of the 
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two drug s for the two end organs of the eigth cranial nerve. 
Ototoxicity occurs less often after treatment with neomyc:i.n 
than with the streptonzycin . 
The morbi dity rates point up the fact that we do not 
know the exact den onunator for determining the incidence of 
drug-induced side effects, since we do not know how many pa -
tients are treated with how rnany courses of the drugs. It 
is possible, and probab le, that many cases of side effects 
g o unnoticed and reverse themselves, or are merely never 
reported, so that the :::. ~~ ~--·- 3 ::.:.v ...... l : _· ::::.·'.:·::-:.~ j_~:, .. : 0 -- ~ ::-- :.~.:.- __;. 
Until data as to the exact nw11.bers of patients tre8.ted with 
drug s, and the exact numbers of carefully follovred patj_ent s 
who manifest side effects associated w:tth these drue;s, are 
8.Vailable for stud~r, it will not be possible to deternrl.ne 
the true inci dence of the side effects in the populati ons 
at risk . Further , in the absence of these same data which 
would otherwise make it possible to calculate dose-ef f ect 
curve relationships for the drugs and their side effects, 
it will not be possib le to determine what dose schedules 
vii ll provide safe limits in rega r ds to producing the side 
effects .. 
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CONCLUSI ONS 
It has been shown that data fro:~'l heterogeneous sources 
collected from the literature -- can b e pooled and analyzed 
systematically to yield meaning f ul results , as if they were 
part of a prospective expel''iment .. 
Analytical procedures which did not yield useful in-
formation in this study of drug side effects we re Spearman 
rank difference correlati on and linear regression coeffi-
cients, when used to investigate the dependence of the 
severity of bone marrovv or audi tory depression on the dose 
of chlor&~phenicol, trimethadione, or st reptomycin. Re gres -
sion a.11a l ys is did yield useful informat.ion relating t o the 
biot ransformation and excretion of chloramphenicol. 
Probi t transfo:r•rr.ati on of cu:mulati ve frequency di stribu-
tions were used to determine the medians of doses and perio ds 
of drug administration which were effective in the product ion 
of side effects in samples of patients in whom the side ef-
fects occurred. Probi t transformations of the percentag e of 
patients who responded to drug s at various levels of dose 
and duration of dl~ug administration were 11sed to determine 
the doses and durations of drug administration wh.ich v:Tere 
effective in producing t h e respective s .ide effects in 50 per 
cent of all patients to whom the drugs were administered. 
The first kind of probit transfo rmat ion , used to compute the 
median Cumulative Effective Dose (CED50 ) or the median 
Cmnulative Effective Time of adniinistration (CET50), surmnari zes 
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the frequency distribution of doses and times; the second 
kind of probit transforrnation, used to compute the median 
Ef:Lecti ve Dose (ED50) or the median Effec ti 'ie Time (ET50), 
summarizes a dose-effect cu1•ve .. 
The Spearman rank difference correlation and linear 
regression coefficients were also used to investig ate the 
dependence of the occul"rence of chloramphenicol-induced 
aplastic anemia on the schedule of drug administration. 
Other tools, such as the Relative Toxicity Index, modified 
from and analog ous to the therapeutic index, were used to 
compal"e certain data obtained in the course of the study. 
Blood levels of hemaglobin, wlnt e-cells, polymorpho-
nuclear leukocytes, and p latelets were found not to be 
dependent on the doses of chloramphenicol, trimethadione, 
or strepto~-cin adminis tered to patients with bone nmrrow 
suppression following use of these drug s, sugsesting that 
there was no dependence of the severity of the si de e f fe ct 
on the dose of the responsible drugs . 
Neither sex nor any age g roup was any more sensitive 
to the toxic effects of chloramphenicol, streptoWJCin , di -
hydrostre ptomy cin, or neonwcin . Tho se who died as a result 
of their chloramphenicol-induced aplastic ane:nJ.ia appeared 
to b e more sensitive to the toxic effects of the drug on the 
bone marrow; but other evidence suggests that those who died 
were not, in fact, more sensitive to the antibiotic. Chlor-
ampheni c ol was more potent than trimethadione or streptomycin 
in producing bone mar rov1 depression. 
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Computati ons of CED50 and ED50 both showed that the 
vestibulal1 apparatus is rilore sensitive to streptomycin than 
is the auditory apparatus , and that the audi tor~r apparatus 
is more sensitive to dihydrostreptomycin than is the ves-
tibular apparatus . Similar relationships among these two 
drug s and two target organs were found in the cat, but that 
species is more sensitive to the drugs than is man. Strep-
tomycin and dih~Tdrostreptomycin were equipotent in the 
production of ototoxi city in general . :N"e omy cin was more 
potent than either, but it did not exhibit specificity for 
either the acoustic or the vestibular apparatus . The data 
also sugg ested that total dose , or total dose/ke;, may be 
more important than da ily dose/kg in the occurrence of 
ototoxicity in populations treated with these antibiotics. 
It is furthe r sugg ested that the CED50 may be used to 
predict the ED50, a n d to dtermine the special selectivity of 
a drug for one of tvvo or more effects, tb:us pe r mitting raore 
parsimonious experime n t al design t han is possible in de -
termininG the ED50 . 
The Relative To.xi c i ty Indices (RTI), which are anal o-
g ou s to but not operationally identical with the therapeutic 
index, supported the findings based on the CED50, CET50, 
ED50 , and ZT50. 
The rates of disappearance from the body of chloram-
phenico l and its metabolite s show that only small amounts 
of the antibiotic can remain in the body 24 hours a:Ltei' 
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discontinuing chronic therapy during which maximum c o dy and 
b lood levels have accumulat ed . The rati o of b lood to tissue 
distribution of chloramphenicol and its metabolites c ould be 
es timated . Further, it was shown that a therapeutic r e g i men 
wollld probably produc e sermn concentrations of chlorampheni -
col f ar in excess of t hose found in patients:~ or ani:mals , 
with acute toxicity :~ in whom hematolog ical cha D.ge s have 
never b een found , so that it c a nnot be ruled out th8.t 
c h loramphenicol-induced apla s tic anemia is a dose-dependent 
phe n ome non . 
Trimethadione was f ound to have a rmJ.ch longer half-life 
in tbe b l ood than chloramphenicol, while stre pto~rci n has a 
half - life simi lar to that of chloramphenicol but it does not 
a ccumulate i n the b lood to the same ex tent as does chloram-
phenicol . 
Patients who developed de pression of on ly one blood 
ce 11 t3rpe associated with chloramphenicol therapy vTer e more 
like l y to be d iaGno sed during the first c ourse of therapy 
with the drug than those who developed pancytopenia . I t 
did not appear l i kely that either panc y topenia or depress ion 
of only one or two blood cell t ypes was equally like l y to 
occur during one c ourse of chl oramphenicol therapy . lTe i t h er 
continuous nor intermi t tent therapy with chloramphenicol 
was found to be rw1.,e li kely than t he other to cause b one 
mar row de pressi on .• 
• 
• 
• 
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Th e validity and limitati ons of the data and the v o.ri-
ous t r eatment s of the data are discusse d . The major 
limitation to complete evaluation of the data as dose - effect 
curves is the l a c k of exact numbers of patients receiving 
the dr tlGS stud.ied , as well as of the total nu1nbers of pa -
tie nts in whom the side effects occur . The most important 
kind of inf ormation which it is poss i ble to derive from 
consideration of the s e data are t hos e relating to the rela-
tive sensitivities of different kinds of patients or t a r g et 
org a n s, or t h ose r e lating to the re l ative potencies of 
diff ere n t drug s i n p r odud. ng the si de effec t s , 

SIDE EFFECT STUDIED (% of patients studied): 
Bone marrow depression 
Depressed acoustic function alone 
Depressed vestibular function alone 
Depressed acoustic & vestibular functions 
TOTAL NUMBER OF PATIENTS STUDIED: 
AGE (range in years) 
(semi-interquartile range, years) 
SEX(% of patients studied): 
Male 
Female 
Sex not reported 
RACE: 
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DIHY-
DRO-
CHLOR- TRI- STREP- STREP- STREP-
AMPHEN- METRA- TOMY- TOMY- TOMY- NEO-
ICOL DIONE CIN CIN CIN MYCIN 
100.0% 100.0% 100.0% 0 % 0 % 0 
0 0 0 40.8 82.0 73.1 
0 0 0 43.7 12.3 0 
0 0 0 15.5 5.7 26.9 
78 16 10 142 219 26 
t-92 6-54 3-76 4-76 3-70 18-79 
2-33 9-20 9-63 27-49 21-42 43-60 
34.6% 25.0% 80.0% 23.2% 19.2% 61.5% 
65.4 75.0 20.0 27.5 16.0 23.1 
0 0 0 49.3 64.8 15.4 
NONE IN ANY SERIES REPORTED TO BE OTHER 
THAN WHITE 
patients studied): 
% 
DISEASES FOR WHICH DRUG PRESCRIBED (% of 
Organisms known to be sensitive to drug 
Organisms not sensitive to drug 
Organisms for which no microbiological 
12.8% 100.0% 64.8% 100.0% 96.2% 
indication for drug was reported 
DURATION OF THERAPY WITH DRUG (range 
(semi-interquartile range, days) 
7.7 0 0 0 0 
79.5 0 35.2 0 3.8 
in days)2-1800 11-360 25-270 1-4880 1-330 3-140 
15-144 84-250 59-113 12-190 23-170 9-34 
TABLE II 
(continued on next page) 
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TABLE II (cont.) 
DIHY-
DRO-
CHLOR- TRI- STREP- STREP- STREP-
AMPHEN- METRA- TOMY- TOMY- TOMY- NEO-
ICOL DIONE ~CI=N~- CIN CIN MYCIN 
NUMBER OF COURSES OF DRUG ADMINISTERED TO EACH PATIENT(% of patients studied): 
One (continuous therapy) 19.2% 93.7% 100.0% 100.0% 100.0% 92.3% 
More than one (intermittent therapy) 50.0 6.3 0 0 0 7.7 
Number of courses not reported 30.8 0 0 0 0 0 
ONSET OF SYMPTOMS OF SIDE EFFECT: DURING THERAPY AND UP TO SIX WEEKS AFTER 
CESSATION OF THERAPY 
SURVIVAL FROM SIDE EFFECT(% of patients studied): 
Recovered 33.3% 18.7% 40~0% 100.0% 100.0% 100.0% 
Died 66.7 81.3 60.0 0 0 0 
LENGTH OF SURVIVAL FROM ONSET OF SYMPTOMS OF SIDE EFFECT, IN FATAL CASES (range in days): 
(semi-interquartile range, days) 
CAUSES OF DEATH(% of patients who died): 
Primary toxic effect of drug 
Diseases for which drug prescribed 
Disease secondary to bone marrow depression 
(hemorrhage due to thrombocytopenia) 
Other intercurrent disease not 
involving bone marrow depression 
Not reported 
7-1800 9-60 1-19 
30-135 15-27 1-16 
0 % 
7.1% 
88.5 
. 2.2 
2.2 
0 
0 
61.5 
23.1 
15.4 
% 0 
0 
100.0 
0 
0 
TABLE II 
General description of all patients included in study. 
% 
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AGE (yrs) 0-10 11-20 21-30 31- 40 41-50 51-60 61-70 71-80 81-90 91-100 TOTALS 
CHLORAMPHENICOL 
MALE 
Died 7 2 2 3 3 1 18 
Recovered 6 1 1 1 9 
TOTAL 13 3 3 3 4 1 27 
FEMALE 
Died 16 6 1 7 2 1 1 34 
Recovered 3 3 3 4 2 2 17 
TOTAL 19 9 4 11 2 3 2 1 51 
TOTALS 32 9 7 11 5 6 6 1 1 78 
TRIMETHADIONE 
MALE 
Died 1 2 3 
Recovered 1 1 
4 
FEMALE 
Died 7 2 1 10 
Recovered 1 1 2 
12 
TOTALS 16 
STREPTOMYCIN 
MALE 
Died 1 1 1 2 5 
Recovered 1 1 1 3 
8 
FEMALE 
Died 1 1 
Recovered 1 1 
2 
TOTALS 1 1 1 3 1 1 2 10 
TABLE III 
Distribution by age, sex , and outcome of side effect of patients who 
developed bone marrow suppression associated with the administration of chloram-
phenicol, trimethadione, and streptomycin. 
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AGE NOT 
AGE (yrs) 0-10 ll-20 21 .. 30 31-40 41-50 51-60 61-70 71-80 REPORTED TOTALS 
STREPTOMYCIN 
MALE 
A* 2 7 8 3 4 24 
V-ld• 2 1 3 1 1 8 
A&V**~" 1 1 
33 
FEMALE 
A* 1 7 4 3 2 17 
v~~* 1 1 2 6 2 5 1 1 19 
A&V~tc*·k 1 1 1 3 
39 
SEX NOT REPORTED 
A-1:: 3 6 4 3 1 17 
V*''c··k 2 5 9 3 16 35 
A&.V-k** 2 3 3 2 3 3 2 18 
70 
TOTALS 5 7 26 28 27 13 14 2 20 142 
DIHYDROSTREPTOMYCIN 
MALE 
A~" 5 3 5 8 4 3 28 
Vi'c"i':: 1 3 4 1 9 
A&V*~'d> 2 1 1 1 5 
42 
FEMALES 
A* 1 4 6 4 2 2 19 
V** 5 4 5 14 
A&Vi'ci'ci'~ 1 1 2 
35 
SEX NOT REPORTED 
A~'( 13 17 36 29 15 15 8 133 
V'J'c"J'c 1 1 2 4 
A&V"ki~-;'c 1 1 1 2 5 
142 
TOTALS 21 25 57 51 32 22 10 1 219 
(continued on next page) 
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AGE NOT 
AGE (yrs) 0-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 REPORTED TOTALS 
NEOMYCIN 
MALE 
A·i<: 2 2 3 1 2 10 
A&V~'d:* 1 1 2 1 5 
FEMALE 
A-l( 1 1 2 1 5 
A&V~'\~-1: 2 2 
SEX NOT REPORTED 
A~': 1 1 1 1 4 
TOTALS 3 1 4 5 7 3 2 1 
STREPTOMYCIN DIHYDROSTREPTOMYCIN NEOMYCIN 
N': 58 180 19 
v~'\~'( 62 27 0 
A&V·-k--;~"";'( 22 12 7 
TABLE IV 
Distribution by age, sex, and f orm of ototoxicity of patients who developed 
ototoxicity associated with the administration of streptomycin, dihydrostrepto-
mycin, and neomycin. 
* A indicates acoustic impairment alone. 
~·d: V indicates vestibular impairment alone. 
*** A&V indicates acoustic and vestibular impairment t ogether. 
15 
7 
4 
26 
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N r t p 
CHLORAMPHENICOL 
Total dose 
HEMOGLOBIN 38 -0.07 0.43 < ·S 
WHITE-CELL COUNT 51 -0.08 0.58 < ·5 
POLYMORPHONUCLEARS 40 +0 .38~·~ 2.69 < -02 
PLATELETS 42 -0.09 0.59 < ·5 
Dose/kilogram 
HEMOGLOBIN 38 +0.07 0.43 <:.S 
WHITE-CELL COUNT 51 +0. 76~'<' 7.90 ( .02 
POLYMORPHONUCLEARS 40 +0 .21 1.40 < .2 
PLATELETS 42 -0.16 1.01 < ·4 
Dose/kilogram/day 
HEMOGLOBIN 38 -0.10 0.64 .( .5 
WHITE-CELL COUNT 51 +0.25 1.90 < ·1 
POLYMORPHONUCLEARS 40 -0.14 o·. 89 <·4 
PLATELETS 42 +0 .13 0.83 .(_. 5 
Duration of Therapy 
HEMOGLOBIN 38 -1-Q .317'<' 2.04 < .OS 
WHITE-CELL COUNT 51 +0.21 1.55 < .2 
POLYMORPHONUCLEARS 40 +0 .31"''~ 2.05 < .OS 
PLATELETS 42 -0.14 0.93 < .4 
TRIMETHADIONE 
Total dose 
HEMOGLOBIN 16 -0. 66~'<' 3.24 .(.01 
WHITE-CELL COUNT 16 +0.45 1.88 < .1 
POLYMORPHONUCLEARS 16 -0.19 0.70 < ·5 
PLATELETS 11 -0. 71* 3.03 <·01 
Dose/kilogram 
HEMOGLOBIN 16 -0. 64~'<' 3.12 ( .01 
WHITE-CELL COUNT 16 +0.38 1.55 ( .2 
POLYMORPHONUCLEARS 16 -0.28 1.10 ( .3 
PLATELETS 11 -0. 77* 3.58 <._.01 
Dose/kilogram/day 
HEMOGLOBIN 16 -0.39 1.56 ~ .2 
WHITE-CELL COUNT 16 +0.22 0.86 < .s 
POLYMORPHONUCLEARS 16 -0.40 1.64 < .2 
PLATELETS 11 +0.02 0.06 ?.9 
Duration of Therapy 
HEMOGLOBI N 16 -0.50 2.13 < .01 
WHITE-CELL COUNT 16 +0 .33>'<' 2. 2 2 < .OS 
POLYMORPHONUCLEARS 16 -0.20 0.75 < ·S 
PLATELETS 11 -0. 52>'~ 1.81 <.OS 
(continued on next page) 
STREPTOMYCIN 
Total dose 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
Dose/kilogram 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
Dose/kilogram/day 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
Duration of Therapy 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
STREPTOMYCIN 
Total dose 
HEARING LOSS (decibels) 
Dose/kilogram/day 
HEARING LOSS (decibels) 
DIHYDROSTREPTOMYCIN 
Total dose 
HEARING LOSS (decibels) 
N 
6 
8 
9 
6 
6 
8 
9 
6 
6 
8 
9 
6 
6 
8 
9 
6 
39 
39 
24 
TABLE V 
r 
-0.71 
-0.15 
-0.33 
+0.46 
-0.49 
-0.15 
-0.15 
+0.08 
-0.31 
-0.22 
o.o 
+0.29 
-0.26 
-0.21 
-0.24 
+0.29 
+0.10 
+0.01 
+0.29 
t 
2.04 
0.37 
0.93 
1.03 
1.11 
0.37 
0.27 
0.15 
0.66 
0.55 
o.o 
0.60 
0.53 
0.52 
0.66 
0.60 
0.70 
0.40 
1.00 
p 
<. .2 
.( .8 
< ·4 
t:_ .4 
.,( . 1 
<·8 
<. 7 
) .9 
(.5 
(. . 7 
1.0 
<_.6 
( .6 
.c, .6 
<·5 ( .6 
( .5 
<· 7 
<.2 
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Correlation of hematological findings with dose in patients with 
bone marrow depression associated with therapy with chloramphenicol, 
trimethadione, and streptomycin, and of dose with number of decibels 
of hearing lost in patients with deafness associated with streptomycin 
and dihydrostreptomycin therapy. ~is the number of patients, £ is 
the Spearman rank difference correlation coefficient, and an asterisk (*) 
indicates a value of £ that is statistically significant, as measured 
by ~' at the R level indicated. 
CHLORAMPHENICOL 
Total dose 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
Dose/kilogram/day 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
TRIMETHADIONE 
Total dose 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
Dose/kilogram/day 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
STREPTOMYCIN 
Total dose 
HEMOGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
Dose/kilogram/day 
HEM:OGLOBIN 
WHITE-CELL COUNT 
POLYMORPHONUCLEARS 
PLATELETS 
STREPTOMYCIN 
Total dose 
HEARING LOSS (decibels) 
Dose/kilogram/day 
HEARING LOSS (decibels) 
DIHYDROSTREPTOMYCIN 
Total dose 
HEARING LOSS (decibels) 
N 
38 
51 
40 
42 
38 
51 
40 
42 
16 
16 
16 
11 
16 
16 
16 
11 
6 
8 
9 
6 
6 
8 
9 
6 
39 
39 
24 
TABLE VI 
b 
+ 0 .OP'• 
1.44 
+ 11.43 
+ 15.01 
o .as ~" 
+194.48* 
- 18.63 
+808 .22~" 
- 28.69 
+ ss. so~·· 
2.18 
1.25* 
1.19 
+ . 2. 28 
+ 0.15 
+ 0.02 
- 11.45 
3.99 
0.74 
+ 0.76 
+ 1.53 
0.75 
0.12 
+ 0.17 
+ 1.34 
+ 0.001 
+ 0.90 
PF 
> .05 
> ·OS 
>·05 
.(.005 
< .005 
..( .005 
< .oos 
< .005 
..( .01 
( .01 
).05 
(.01 
,..as 
) .05 
.,. .os 
L .01 
> .OS 
) .05 
).05 
'>.05 
)>-.05 
') .05 
> .05 
~ .OS 
.) .05 
> .OS 
s;: .o1 
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Regression analyses for dose and hematological findings in patients 
with bone marrow depression associated with therapy with chloramphenicol, 
trimethadione, and streptomycin, and for dose and number of decibels of 
hearing lost in patients with deafness associated with streptomycin and 
dihydrostreptomycin therapy. ( . d ) 
contlnue on next page 
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~ is the number of patients in each group, £ is the slope of the regression 
line, an asterisk (*) indicates values of£ which are significant at the 
p 0.05 level, and Pp is a measure of linearity, indicating t he probability 
that the points from which the regression time was calculated are related 
in a linear fashion. 
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p 
N CEDSO 95% c. L. s 95% c. L. F 
Total dose, g 57 16.3 11.6-23 .o 3.8 3.0-4.9 -< .001 
Total dose/kg,mg 57 420.0 325.6-541.8 2.7 2.3-3.3 < .01 
Daily dose/kg,mg 65 9.4 6.2-14.3 5.9 4.4-7.9 (.01 
Males, total dose, g 18 11.3 6.5-19.5 3.3 2.2-4.3 <.001 
Females, total dose, g 39 18.5 12.8-26.8 3.4 2.6-4.4 <.001 
Males, mg/kg 18 340.0 219.4-527.0 2.6 1.9-3.5 ( .01 
Females , mg/kg 39 470.0 340.6-648.6 2.8 2.3-3.5 <.OS 
Males, mg/kg/day 22 11.2 5.3-23.5 6.0 3.6-9.9 < .OS 
Females, mg/kg/day 43 7.6 4.6-12.7 5.4 3.7-7.8 £.01 
0-13 yrs, total dose, g 22 6. s~·~ 4.2-10.1 2.9 2.1-4.0 <.os 
14-30 yrs, total dose, g 12 36.0 18.0-72.0 3.4 2 .1-5.6 < .OS 
30 yrs, total dose, g 23 23.5 15.8-35.0 2.7 2.0-3.6 <.OS 
0-13 yrs, mg/kg 22 335.0 212.0-529.3 3.0 2.2-4.1 <.Ol 
14-30 yrs, mg/kg 12 540.0 295.1-988.2 2.9 1.9-4.5 < .05 
30 yrs, mg/kg 23 . 335.0 214.7-522.6 3.0 2.2-4.1 <.01 
0-13 yrs, mg/kg/day 30 10.5 5.5-20.2 6.2 3.9-9.9 < ·001 
14-30 yrs, mg/kg/day 13 5.8 2.3-14.5 5.2 2.8-9.8 < .05 
30 yrs, mg/kg/day 22 4. 7 2.9-7.5 3 .P'~ 2.3-4.3 <( .05 
Died, total dose, g 41 14.0 9.3-21.0 3.8 2.9-5.1 <: .Ol 
Recovered, total dose, g 16 27.0 11.2-65.3 6.2 3. 7-11.8 <;,.01 
Died, mg/kg 41 338.0* 250.4-456.3 2.7 1.1-6.5 < .Ol 
Recovered, mg/kg 16 650.0* 386.9-1092.0 2. 9 2.0-4.2 < .OS 
Died, mg/kg/day 40 6 .3~'<' 4.1-9.8 4.2 3.1-5.7 ( .01 
Recovered, mg/kg/day 23 17. s~"' 9.9-31.0 4.2 2.7-6.3 <.OS 
TABLE VII 
Medians of the doses of chloramphenicol which were effective in producing 
aplastic anemia in patients manifesting the side effect. ~ is the number of 
patients in each group; CEDSO is the median dose of the drug required to 
produce the side effect, with its 95% confidence limits; £ is the slope 
function, with its 95% confidence limits; and PF indicates the probability 
that the plots are not linear. An asterisk indicates values of CEDSO and £ 
which are significantly different from all others in the same group bounded 
by horizontal lines. 
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N CED50 95% C, L, s 95% C, L, 
p 
F 
Total dose, g 16 105,0 70,0-157,5 2,3 2,0-4,0 < ,05 
Total dose/ kg, mg 16 3000,0 2300,0-4000,0 1,9 1,5-2.4 < .05 
Daily dose/ kg, mg 16 20,0 15.0-26,6 1,8 1,5- 2,3 < ·01 
TABLE VIII 
Medians of the doses of trimethadione which were eff ective in producing 
bone marrow depression in patients manifesting the side effect, B is the number 
of patients in each group ; CED50 is the median dose of the drug required to 
produce the side effect, with its 95% confidence limits;~ is the slope function, 
with its 95% confidence limits; and PF indicates the probability that the plots 
are not linear, 
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N CED50 95% C, L, s 95% c, L, PF 
Total does, gm 10 100 61,7-162,0 2.2 1,6-3,1 ( .001 
Total dose/ kg, mg 10 1230 798, 7-189Lj.,2 2,0 1,5-2,7 ( ,05 
Daily dose/ kg, mg 10 22 16,5-29,3 1,6 1,3-2,0 ( .01 
TABLE IX 
Medians of the doses of streptomycin which are effective in producing 
bone marrow depression in patients manifesting the side effect, B is the 
number of patients in each group; CED50 is the median dose of the drug required 
to produce the side effect, with its 95% confidence limits; ~ is the slope 
function, with its 95% confidence limits; and Pp indicates the probability that the 
plots are not linear, 
Total dose, g 
Total dose/kg,mg 
Daily dose/kg,mg 
Males, total dose, g 
Females, total dose, g 
Sex not reported, total 
Males, mg/kg 
Females, mg/kg 
Males, mg/kg/day 
Females, mg/kg/day 
0-30 yrs, total dose, g 
31-50 yrs, total dose, g 
>SO yrs, total dose, g 
0-30 yrs, mg/kg 
31-50 yrs, mg/kg 
>50 yrs , mg/kg 
0-30 yrs, mg/kg/day 
31-50 yrs, mg/kg/day 
? 50 yrs, mg/kg/day 
A, total dose, g 
V, total dose, g 
A&V, total dose, g 
A, mg/kg 
V, mg/kg 
A, mg/kg/day 
V, mg/kg/day 
N CEDSO 95% C. L. s 
142 
89 
90 
77 .o 
930.0 
12 .o 
53.8-91.0 5.2 
704.5-1227.6 3.7 
8.9-16.2 4.3 
33 
39 
dose70 
33 
39 
33 
39 
38 
55 
29 
14 
30 
26 
14 
30 
26 
76.0 46.9-123.1 
28.0* 16.1-28.7 
75.0 65.2-86.3 
1040.0* 666.7-1622.4 
570.0* 325.7-997.5 
5.6~~ 4.1-7.7 
10.7~~ 8.6-13.4 
72.0 46.2-112.3 
85.0 54.8-131.8 
36.0* 19.5-66.6 
1300.0 500.0-3380.0 
1300.0 666.7-2535.0 
240.0* 100.0-576.0 
9.0 5.9-13.8 
6.0 4.4-8.2 
10.3 7.6-13.9 
58 173 .0* 136.2-219.7 
16.2-27.3 
41.0-99.8 
62 21.0* 
22 64.0* 
43 2900.0* 
42 240 .a~~ 
41 4.6* 
42 27 .2~~ 
TABLE X 
2248-3741 
178-324 
3.8-5.5 
23.1-32.0 
4.2 
6.9 
1.8 
3. 7 ~~ 
7.3 
2.5 
2.1 
4.1 
5.3 
5.9 
6.6 
7.9 
9.2 
2.2 
2.4 
2.2 
2.5 
2.9 
2.9 
2.4 
2.7 
1.8 
1.7 
95% C. L. 
4.3-6.3 
3.6-3.9 
3.5-5.3 
3.0-5.9 
4. 6-10.3 
1.7-2.0 
2.7-5.1 
4.8-11.1 
2.0-3.2 
1.8-2.5 
3.0-5.6 
3.9-7.1 
3.8-7. 9 
3.4-12. 9 
4.8-13.0 
5.1-16.7 
1.7-3.0 
1.9-3.0 
1.8-2.7 
2.2-3.0 
2.4-3.5 
2.2-4.0 
2.0-2.9 
2.2-3.3 
1.3-2.5 
1.5-1.9 
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(.01 
(.05 
<.os 
<.os 
<.OS 
(.01 
(.05 
<.01 
.(.01 
<.01 
<.os 
<.Ol 
.(.05 
.(.1 
(.05 
<.OS 
<,.01 
<.05 
< .05 
(.1 
<..05 
(.05 
.(.05 
Medians of the doses of streptomycin which were effective in producing 
ototoxicity in patients manifesting the side effect. ~ is the number of 
patients in each group; CEDSO is the median dose of the drug required to 
produce the side effect, with its 95% confidence limits; ~ is the slope 
function, with its 95% confidence limits; and PF indicates the probability 
that the plots are not linear. An asterisk indicates values of CEDSO or~ 
which are significantly different from all others in the same group bounded 
by horizontal lines. 
A indicates acoustic impairment alone. 
V indicates vestibular impairment alone. 
A&V indicates acoustic and vestibular impairment together. 
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N CEDSO 9S% C, L, s 9S% c, L, PF 
Total dose, g 240 .47 ,0 40,0-SS.2 3,6 3.3-4,0 ( .os 
Total dose/kg,mg 77 780,0 609,4-998.4 3,1 2,6-3,7 < ·OS 
Daily dose/kg,mg 71 19,8 17.2-22,8 1,8 1,6-2,0 < ,OS 
Males, total dose, g 63 130,0~" 98.S-171,6 3,1 2.4-3,7 ( ,OS 
Females, total dose, g 3S 39.0 27.S- SS,4 2.9 2,2-2,7 .(,OS 
Sex not reported,total dosel42 36,0 30,4-42,7 2,8 2.3-3.4 ( .OS 
Males, mg/kg 42 1140~0 919,4-1413,6 2,0 1,7-2,4 .( .01 
Females, mg/kg 3S 860,0 S81~1-1272,8 3~3 2,S-4.3 .( ,OS 
Males, mg/kg/day 38 18,8 16 .• 0-22,1 1.7 1,6-1,9 .( .OS 
Females, mg/kg/day 33 23,3 19.7-27.6 1,7 1,6-1,9 < .os 
0-30 yrs, total dose,g 103 3S,O 29,4-41.7 2,S 2,3-2,8 < -01 
31-SO yrs, total dose,g 83 38,0 31,1-46,4 2,S 2,3-2,8 .(.OS 
>50 yrs, total dose, g 32 28,S* 20,2-40,2 2,7 2.1-3,S .( ,OS 
0-30 yrs, mg/kg 33 1100,0 738~3-1639,0 3,3 2.S-4,3 ( ,01 
31-SO yrs, mg/kg 36 670,0 48S,S-924,6 2.7 2.1-3,S < .1 
> 50 yrs, mg/kg 7 450,0 15S,2-1305,0 4.2 1,9-9,2 <. .os 
0-30 yrs, mg/kg/day 30 19,5 1S,0-2S,4 2,1 1,8-2,5 < ,OS 
31-50 yrs, mg/kg/day 34 18,7 14,8-23,6 2,0 1,7-2,4 <: .01 
>SO yrs, mg/kg/day 7 13,3 7,6-23,3 2,1 1.4-3.2 .( .os 
A, total dose, g 180 32,5"k 27,5-38,4 3,2 2,9-3,5 ( ,05 
v, total dose, g 48 182~0~" 134.8-245.7 2,8 2,3-3,4 z .os 
A&V, total dose, g 12 91;0* ss.S-149,2 2.4 1.7-3,4 ( ,01 
A, mg/kg 47 630,0~" 427,1-929,3 3,9 3,0-S~l < ,Ol 
V, mg/kg 23 1300,0 1040,0-1625,0 1~8 1.5-2,2 < ,05 
A&V, mg/kg 7 2250,0 1285,7-3937,5 2~1 1,4-3,2 < ,001 
A, mg/kg/day 41 14.3 11,8-17.3 1,9 1,7-2 .. 1 ( .. 01 
V, mg/kg/day 23 14,0 11,1-17,6 1,8 1~ 5-2,2 <. ,01 
A&V, mg/kg/day 7 28 ,o.,.~ 18,2-43,1 1,8 1,3-2,5 <. ,1 
TABLE XI 
Medians of the doses of dihydrostreptomycin which were effective in 
producing ototoxicity in patients manifesting the side effect, ~ is the number 
of patients in each group; CEDSO is the median dose of the drug required to 
produce the side effect, with its 95% confidence limits; ~ is the slope 
function, with its 9S% confidence limits; and PF indicates the probability 
that the plots are not linear, An asterisk indicates values of CEDSO or ~ 
which are significantly different from all others in the same group bounded 
by horizontal lines, 
A indicates acoustic impairment alone, 
V indicates vestibular impairment alone, 
A&V indicates acoustic and vestibular impairment together, 
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N CEDSO 9S% c. L, s 9S% c. L. PF 
Total dose, g 2S 13.S 10,9-16.7 1.7 1.4-2.0 < ,001 
Total dose/kg,mg 21 27S.O 197.8-382.3 2.2 1.7-4.0 <.os 
Daily dose/kg,mg 21 11,1 7.6-16.3 2.S 1.9-3.3 <.os 
Males, total dose, g lS 1S.8 11.9-21.0 1.8 l.S-2.2 (.01 
Females) total dose 2 g 6 15.8 10~3-24.3 1.7 1.2-2.4 ~.01 
Males, mg/kg lS 20S.O 148.6-282.9 1.9 l.S-2.5 (.01 
Females 2 mgLkg 6 242.0 162.4-360,6 1.7 1.3-2.2 ~,01 
Males, mg/kg/day lS 9.6 S.4-17 .o 3 .1;\' 2.1-4.7 (.os 
Females) mgLkgLday 6 14.3 10.8-19.0 1.4 1.2-1. 7 (,01 
o-so yrs, total dose, g 12 13.2 9.S-18.3 1.8 1.4-2.3 (.01 
'>SO yrs 2· total dose 2 g 12 13.S 9.9-18.4 1.8 1.4-2,3 ~.01 
0-SO yrs, mg/kg 11 21S.O 1S4.7-298.9 1.8 1.4-2.3 < .01 
l;SO yrs 2 mgLkg 10 22S.O 1S7.3-321.8 1.8 1.4-2,) ~,01 
0-50 yrs, mg/kg/day 11 12.2 8.8-16.8 1.7 1.3-2.2 <.OS 
.>so yrsl mgLk8Lday 10 9.7 6.8-13.9 L8 1.3-2.3 (.01 
A, total dose, g 18 13.3 9.7-18.2 2.0 l.S-2.6 (_.os 
A&V 2 total dose l g 7 13.0 10.8-1S.6 1.3 1.2-1,6 ~.01 
A, mg/kg 14 320~0;\' 210.S-486.4 2.2 1. 7-2.9 (.01 
A&V 2 mgLkg 7 1S7.0* 113.8-216.7 l.S 1.2-2.0 (.01 
A, mg/kg/day 13 lS.O 12.2-18.S l.S;': 1.3-1.8 <·Ol 
A&V 2 mgLkgLday 8 s.o 1.2-2l.S 7.6 2. 7-21.3 (.001 
TABLE XII 
Medians of the doses of neomycin which were effective in producing 
ototoxicity in patients manifesting the side effect. B is the number of 
patients in each group; CEDSO is the median dose of the drug required to 
produce the side effect, with its 9S% confidence limits; ~ is the slope function, 
with its 95% confidence limits; and PF indicates the probability that the 
plots are not linear. An asterisk indicates values of CEDSO or~ which are 
significantly different from all others in the same group bounded by 
horizontal lines. 
A indicates acoustic impairment alone, 
A&V indicates acoustic and vestibular impairment. 
DillY-
DRO-
CHLOR- TRI- STREP- STREP- STREP-
DOSE AMPHEN- METRA- TOMY- TOMY- TOMY- NEOMY-
SAMPLE METAMETER ICOL* DIONE~'<" CIN* CIN** CIN*~'<" CIN*'k 
Total Total (g) 16,3 105,0 100,0 70,0 47,0 13.5 
Total Dose/kg (mg) 420.0 3000,0 1230,0 930,0 700,0 275.0 
Total Dose/kg/day (mg) 9.4 20,0 22,0 12,0 19.8 11.1 
Males Total (g) 11,3 76,0 130.0 15,8 
Females Total (g) 18,5 28,0 39,0 15.8 
Males Dose/kg (mg) 340,0 1040,0 1140,0 205.0 
Females Dose/kg (mg) 470,0 570,0 860,0 242.0 
Males Dose/kg/day (mg) 11,2 5,6 18.8 9,6 
Females Dose/kg/day (mg) 7~6 10.7 23,3 14,3 
A Total (g) 173.0 32,5 13,3 
v Total (g) 21.0 182.0 
A&V Total (g) 64,0 91.0 13,0 
A Dose/kg (mg) 2900.0 630.0 320.0 
v Dose/kg (mg) 240,0 1300,0 
A&V Dose/kg (mg) 2250.0 157.0 
A Dose/kg/day (mg) 4.6 14.3 15.0 
v Dose/kg/day (mg) 27.2 14.0 
A&V Dose/kg/day (mg) 28.0 5,0 
TABLE XIII 
CED50 values for chloramphenicol, trimethadione, streptomycin, 
dihydrostreptomycin, and neomycin, abstracted from Tables VII-XII, ! is 
depressed acoustic function alone, Y. is depressed vestibular function alone, 
and A&V is depressed acoustic and vestibular functions occurring together, 
One asterisk (*) indicates drugs associated with bone marrow depression, and 
two asterisks (**) indicate drugs associated with ototoxicity, 
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CETSO 
N ~daY:s2 95% c. L. s 95% c. L. Pp 
CHLORAMPHENICOL 
Total sample studied 69 45.5 31.0-69.9 5.4 4.1-7.1 <.os 
Males 23 31.5* 19.3-51.3 5.7 3.5-9.4 < .OS 
Females 46 57 .4~" 41.6-79.2 5.2 3.7-7.3 < .OS 
0-13 yrs 34 26. 6•" 19.0-37.2 4.2 3.0-5.9 < .OS 
14-30 yrs 12 84.0 so. 9-138.6 3.5 2.1-5.8 < .01 
30 yrs 23 65.1 44.9-94.4 3.6 2.2-5.2 <.OS 
Died 47 51.8 37.3-72.0 5.8 4.1-8.1 < .Ol 
Recovered 22 35 .o 21.3-57.4 5.7 3.5-8.0 < .OS 
TRIMETHADIONE 
Total sample studied 16 147.5 98.0-220.5 2.3 2.0-4.0 ( .05 
STREPTOMYCIN 
Total sample studied 10 81.0 60.0-109.4 1. 6 1.3-2 .o ( .01 
TABLE XIV 
Medians of the times of administration of chloramphenicol, trimethadione, 
and streptomycin which were effective in producing bone marrow depression in 
patients manifesting the side effect. ~ is the number of patients in each 
group; CEDSO is the median time of administration of the drug required to 
produce the side effect, with its 95% confidence limits; and Pp indicates the 
probability that the plots are not linear. An asterisk indicates values of 
CEDSO or ~ which are significantly different from all others in the same 
group bounded by horizontal lines. 
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CET·SO 
N ~days2 95% c~ L. s 95% c~ L. PF 
STREPTOMYCIN 
Total sample studied 90 48 32.3-69.8 7.7 5.5-10.8 <.os 
Males 32 150* 69.8-322.5 11.4 6.5-19.9 <.OS 
Females 40 27* 13.3-53 .o 11.5 7.0-19.3 ,<:.OS 
0-30 yrs 14 145* 58.0-362.5 6.6 3.4-12.8 <·05 
30-50 yrs 30 54~"' 27.0-108.0 7.3 4.6-11.7 ( .01 
.> SO yrs 26 lSi( 7.9-29.5 5.8 3.7-9.2 <.OS 
A 41 510* 346.9-749.7 3.5 2.6-4.5 ( .1 
v 43 lP"' 7.8-16.3 3.5 2.7-4.6 { .05 
DIHYDROSTREPTOMYCIN 
Total sample studied 114 63 48.5-81.9 4.3 3.6-5.2 .{.OS 
Males 62 130~'<' 97.7-172.9 3.2 2.7-3.8 .(.01 
Females 32 39~'<" 28.9-52.7 2.4 2.0-2.9 <.OS 
Sex not reported 20 9"k s.8-14.o 2.8 2.0-3.9 <:.05 
0-30 yrs 36 43 ' 31.4-58.9 2.7 2.1-3.5 (.OS 
30-50 yrs 43 41 25.3-66.4 5.2 3.7-7.3 (.OS 
>so yrs 13 19 6.6-55.1 7.5 3.6-15.8 ( .01 
A 64 31* 19.6-49.0 7.3 5.2-10.2 <.os 
v 43 180~'<" 118.4-2 73.6 4.1 3.2-5.3 <·01 
A&V 7 70~'<" 54.7-89.6 1.4 1.2-1. 7 <.OS 
NEOMYCIN 
Total sample studied 26 18 12.4-26.1 2.7 2.1-3.5 <.ol 
Males 16 22* 15.0-32.3 2.2 1.7-2.9 ~.OS 
Females 6 10* 6.5-15.3 1.7 1.2-2.2 (.01 
0-50 yrs 13 16 10.3-24.8 2.2 1.6-3.1 <..Ol 
.>- so yrs 12 23 14.4-36.8 2.3 1. 6-3.2 <..OS 
A 19 19 13.1-27.6 2.3 1.8-3.9 < .Ol 
A&V 7 16 5.9-43.2 3.8 1.8-8.0 <.OS 
TABLE XV 
Medians of the time~ of administration of streptomycin, dihydrostreptomycin, 
and neomycin which were effective in producing ototoxicity in patients 
manifesting the side effect. B is the number of patients in each group; 
CEDSO is the median time of administration of the drug required to produce 
the side effect, with its 95% confidence limits; ~ is the slope function, 
with its 95% confidence limits; and PF indicates the probability that the 
plots are not linear. An asterisk indicates values of CEDSO and~ which 
are significantly different from all others in the same group bounded by 
horizontal lines. 
A indicates acoustic impairment alone. 
V indicates vestibular impairment alone. 
A&V indicates acoustic and vestibular impairment together. 
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DIHY-
DRO-
CHLOR- TRI- STREP- STREP- STREP-
AMPHEN- METRA- TOMY- TOMY- TOMY- NEO-
SAMPLE I COL''' DIONE* CIN~'' CIN'h'' CIN~'<'~'<' MYCIN·k'k 
Total 45.5 147.5 81.0 48 63 18 
Males 31.5 150 130 22 
Females 57.4 27 39 10 
A 510 31 19 
v 11 . 180 
A&V 70 16 
TABLE XVI 
CET50 values (in days) for chloramphenicol, trimethadione, streptomycin, 
cihydrostreptomycin, and neomycin, abstracted from Tables XIV and XV. 
! is depressed acoustic function alone, Y is depressed vestibular function 
alone, and A&V is depressed acoustic and vestibular function occurring 
together. One asteri6k (*) indicates drugs associated with bone marrow 
depression, and two asterisks (**) indicate drugs associated with 
ototoxicity. 
STREPTOMYCIN 
A, total dose, g 
V, total dose, g 
A, dose/day ,g 
V, dose/day,g 
DIHYDROSTREPTOMYCIN 
A, total dose, g 
V, total dose, g 
A, do se/day, g 
V, dose/day, g 
STREPTOMYCIN 
A, duration, days 
V, duration , days 
DIHYDROSTREPTOMYCIN 
A, duration, day s 
V, duration, days 
N EDSO 
---
8029 1100 •k 
7980 180 ~" 
11728 3 .6"l'<: 
11802 1.8.,., 
613 20S 
* S36 340 ~" 
43S4 2. 8~" 
41S7 3 ~ o~·, 
N ETSO 
7889 410 ..,,~ 
7661 13S ";~ 
737 140 * 
760 210 .. k 
TABLE XVII 
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9S% c. L, s 9S% c. L. ~ 
lOS0-11S3 7 • p'c 6.2-8,2 < .001 
162-200 3.2 2,9-3,S < .OS 
3.4-3.9 2 .1 1.9-2.3 < .02S 
1.7-1.9 1.6 l.S-1,7 < .OS 
192-219 2.0 1.9-2.1 < ,OS 
317-36S 2.0 1.8-2.1 < .OS 
2,7-3.0 1.6 l.S-1.7 <.os 
2.8-3,2 1.7 1,6- 1.8 < .OS 
9S% c. L, s 96% c. L, ~ 
366-4S8 4.l~'c 3.6-4.7 ..(.OS 
12S-146 2 • Sic 2~3-2,7 { .OS 
13S-14S 1.4~"' 1.3-l,S < .Ol 
201-219 1,6* l.S-1.7 < .01 
Median effective doses (EDSO) and durations of administration (ETSO) of 
streptomycin and dihydrostreptomycin which produced ototoxicity in the total 
samples to whom the drugs were administered, and the 9S% confidence limits. 
~ is the slope function, with its 9S% confidence limits. P1 2 indicates the 
probability that the plots are not linear, An asterisk to the right of an 
EDSO, ETSO, or~ value indicates a value which is significantly different 
from the other value in the same group. The two drugs were also statistically 
signif icantly different from each other for each side effect in terms of 
EDSO f or each dose metameter and in terms of ETSO and ~. 
A indicates acoustic impairment. 
V indicates vestibular impairment. 
It could not be ascertained from the original data in how many patients 
these two side effects occurred together, 
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ED 50 ET50 CED50 CET50 % ED % ET 
(total dose, (days) (total dose, (days) 
gm.) gm.) 
STREPTOMYCIN 
Acoustic impairment 
1100 173 17.2 
410 510 56.0 
Vestibular impairment 
180 21 3.2 
135 11 0.4 
DIHYDROSTREPTOMYCIN 
Acoustic impairment 
205 32.5 0.4 
140 31 0.1 
Vestibular impairment 
340 182.0 17.0 
210 180 38.0 
TABLE XVIII 
Comparison of CED50 1 s and CET50 1 s for patients exhibiting ototoxicity 
associated with treatment with streptomycin and dihydrostreptomycin with ED50 1 s 
and ET50 1 s development of ototoxicity in all patients treated with the two 
drugs. /~D and /~T indicate the points on the curves for the ED50 and ET50 at 
which the respective values for CED50 and CET50 lies. 
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Relative 
Tox icity 
Recommended '~ CED50 & CET50 ED50 & ET50 Index'"* 
Daily Duration Total Daily Duration Total Daily Duration Total Daily Total 
dose of tmt. dose dose of trot. dose dose of trot. dose dose dose 
(gm) (days) (gm) (gm) (days) (gm) (gm) (days) (gm) 
**"k *"J":"k *";'C"i~ 
--
CHLORAMPHENICOL 
Bone marrow depression: 
3 10 30 0.36 45.5 16.3 0.12 0.54 
TRIMETHADIONE 
Bone marrow depression : 
0.9 ad lib ad lib o. 71 147.5 105 0.74 
STREPTOMYCIN 
Bone marrow depression: 
2 360+ 720+ 1.24 81 100 0.62 0.14 
Acoustic impairment: 
0.34 510 173 0.17 0.24 
2.68 410 1100 1.34 1.53 
Vestibular impairment: 
1.91 11 21 0.96 0.03 
1.34 135 180 0.67 0.25 
Acoustic and/or vestibular impairment: 
64 0.09 1 
Ototoxicity in general: 
1.46 48 70 0.73 0.1 
DIHYDROSTREPTOMYCIN 
Acoustic impairment: 
2 360+ 720+ 1.05 31 32.5 0.53 0.05 
1.46 140 205 0.73 0.29 
Vestibular impairment: 
1.01 180 182.0 0.51 0.25 
1.62 210 340 0.81 0.47 
Acoustic and/or vestibular impairment: 
1.30 70 91.0 0.65 0.13 
Ototoxicity in general: 
0.75 63 47.0 0.38 0.07 
NEOMYCIN 
Acoustic impairment: 
.( 1 ( 10 < 10 0.70 19 13.3 1.00 1.90 
(0.7 g. C< 7 .o) Acoustic & vestibular impairment: 
pure 0.81 16 13.0 1.16 1.86 
base Ototoxicity in general: 
"J'Ck"k"J~) 0.75 18 13.5 1.07 1.93 
(legend on nex t page) 
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TABLE XIX 
Relative toxicity indices for chloramphenicol, trimethadione, streptomycin, 
dihydrostreptomycin and neomycin. 
*Dose schedules recommended by literature accompanying packaged drugs, 
and by Goodman & Gilman (122) 
~h·~ Calculated as ratio of CEDSO or EDSO to recommended dose. 
*** Calculated as ratios of data in adjoining two columns. 
**** The CEDSO data are calculated on the basis of pure neomycin base. 
-97-
Subject N b a c PF Tl 7 (hrs) 
Total Nitro Com2ounds 
A 11 -0.07 92 6.0 (.01 4.0 
B 11 -0.07 106 7.6 < .Ol 4.3 
c 8 -0.08 72 25.3 < -01 2.5 
D 8 -0.07 85 28.9 ( .01 3.9 
E 8 -0.06 110 13.5 .( .01 5.3 
F 6 -0.06 54 21.9 ( .1 1.4 
G 6 -0.07 125 0.7 .( .01 4.6 
H 6 -0.08 117 16.2 < ·01 3.8 
I 5 -0.06 138 8.9 .( .01 5.1 
J 4 -0.07 95 12.1 <.01 4.2 
K 5 -0.13 656 19.4 { .01 1.3 
X± S.D. -o.o7±o.oo6 3. 7±1.36 
Active Chloram2henicol 
A* 8 -0.14 143 0.7 <·01 2.2 
B* 10 -0.07 158 0.1 z .o1 4.4 
c~\"~': 7 -0.12 76 0.6 .( .01 2.2 
D-I("J~ 7 -0.09 112 0.3 < -01 3.6 
E"ki'\ 7 -0.07 128 0.1 .( .01 4.6 
- + X - S.D. -o .10±o .031 + 3.4-1.16 
Inactive Metabolites***: 
A 10 -0.08 118 0.2 z: .ol 5.3 
B 10 -0.08 107 0.1 _( .01 4.1 
c 7 -0.09 108 1.0 ( .01 3.3 
D 7 -0.07 125 1.0 .( ·01 4.3 
E 7 -0.07 137 0.1 z .ol 4.6 
- + X - S . D. -o.o8±o.o1 + 4.3-0.73 
TABLE XX 
(legend on next page) 
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TABLE XX (cont.) 
Rates of urinary excretion of chloramphenicol, as measured by total nitro 
compounds, active chloramphenicol, and inactive metabolites of chloramphenicol, 
in the urine. ~ is the number of samples which were collected; Q is the linear 
regression coefficient for the plot of the logarithm of the percent of the total 
recoverable amount of the compound remaining in the body against time after 
administration of the dose (after rectification of the curve);£ is the c-value 
described in the text; ~ is the intercept of the line; Pp indicates the 
probability that the plots are not linear; and ~ is the half-li f e of the compound 
in the body. Each letter represents one subject to whom one dose was given as 
listed below: 
A: 1.5 
B: 0.5 
c: 0.5 
D: 0.5 
E: 0.5 
F,G ,H: 
I , J ,K: 
gm chloramphenicol 
gm chloramphenicol 
gm chloramphenicol 
gm chloramphenicol 
gm chloramphenicol 
Dose equivalePt of 
ester p.o. (120) 
Dose equivalent of 
stearoyl-glycolate 
p. 0. (121) 
p.o. (121) 
capsule p.o. (125) 
tablet p.o. (125) 
palmitate suspension p.o. (125) 
1.5 gm chloramphenicol given a s the palmitate 
1.5 gm chloramphenicol given as the 
ester p.o. (120) 
* Active chloramphenicol assayed by microbiological technique. 
**Active chloramphenicol assayed by colorimetric technique. 
*** Inactive metabolites determined by subtracting the milligrams of 
active chloramphenicol f rom the milligrams of total nitro compounds. 
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Subject N b a c PF Tk 2 (hrs) 
Total Nitro Compounds 
I 5 -0.19 121 4.2 .( .01 1.7 
II 5 -0~14 107 0.9 < .01 2.2 
III 5 -0.22 167 2.1 < .01 1~4 
IV 5 -0.21 154 0.8 < ·01 1.5 
v 6 -0.10 48 0.1 < ·05 0.21 
VI 5 -0.21 151 0.7 { .01 2.8 
-+ S.D. + + x - -0.18-0.048 1.6-0.78 
Active Chloramphenicol i~: 
I 5 -0.22 138 0.1 <.01 1.5 
II 5 -0.21 86 0.7 ( ·01 1.3 
III 5 -0.22 151 0.4 ( ·01 1.5 
-+ x- S.D. + -0.22-0.004 + 1.4-0.12 
Inactive Metabolites **: 
IV 5 -0.25 339 0.2 (_.05 0.9 
v 5 -0.23 195 0.3 ( .01 1.3 
VI 5 -0.25 240 0.7 ~ .01 1.0 
-+ S.D . + + x - -0.24-0.012 1.1-0.21 
TABLE XXI 
Rates of disappearance of chloramphenicol from the blood, as measured by 
total nitro compounds, active chloramphenicol, and inactive metabolites of 
chloramphenicol, in serum. B is the number of blood samples which were collected, 
Q is the linear regression coefficient for the plot of the logarithm of the 
percent of the total recoverable amount of the compound remaining in the body 
against time after administration of the dose (after rectification of the curve), 
c is the c-value described in the text; ~ is the intercept of the line; 
Pp indicates the probability that the plots are not linear; and~ is the half-life 
of the compound in the body. Each roman numeral represents one group of subjects 
to whom doses were given are listed below: 
All data from which this table was calculated were given as means for 
groups of normal volunteers, and single dose equivalents of 1.5 g chloramphenicol 
were administered to all subjects orally in preparations noted below: 
I. Mean for 4 subjects, palmitate suspension.(l20) 
II. Mean for 4 subjects, capsules. (120) 
III~ Mean for 4 subjects, stearoyl-glycolate ester. (120) 
IV. Mean for 3 subjects, capsules. (120) 
v. Mean f or 3 subjects, palmitate suspension. (120) 
Vi. Mean for 3 subjects, stearoyl-glycolate ester. (120) 
(continued on next page) 
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TABLE XXI (cont.) 
* Active chloramphenicol assayed by microbiological technique. 
~'d'> Inactive _metabolites determined by subtracting milligrams of 
active chloramphenicol from milligrams of total nitro compounds. 
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Total Nitro Com~ounds Chloram~henicol Inactive Metabolites 
b Blood -0.18 ± 0.048 -0.22 ± 0.004 -0.24 ± 0.012 
b Urine -0.07 ± 0.006 -0.10 ± 0.031 -0.08 ± 0.01 
T% Blood 1.6 + 0.78 hrs 1.4 ± 0.12 hrs 1.1 ± 0.21 hrs 
Tlz Urine 3.7 ± 1.36 hrs 3.4 ± 1.16 hrs 4.3 ± 0.73 hrs 
TABLE XXII 
Comparison of rates of excretion (£) of chloramphenicol, as determined 
by total nitro compounds, active chloramphenicol, and inactive nitro metabolites 
of chloramphenicol, measured in blood and urine, and comparison of half-life (11) 
of chloramphenicol in the body, similarly determined. 
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Amount remalnlng in 
body 24 hours after 
Time to reach last dose after 
Yn(max) (mg) Yn(max) (hr) attaining Yn(max) T]z (hr) (mg) 
ACTIVE 
CHLORAM-
PHENICOL 3.4 675 19.2 8.96 
INACTIVE 
METABOLITES 4.3 3618 28.7 127.55 
TOTAL NITRO 
COMPOUNDS 3.7 4846 28.5 143. 26 
TABLE XXIII-A 
Max imum body levels (yn(max)) of microbiologically active chloramphenicol, 
its microbiologically inactive metabolites, and total nitro compound s , 
obtainable after initiation of therapy with a hypothetical daily dose of 
50 mg/kg administered to a 70-kg human subject in equal doses every 6 hours. 
These data are based on determinations of chloramphenicol and i ts der iva tives 
in the urine, and so estimate the amounts of these compounds presen t in the 
whole body and not in the plasma alone. The calculations are more fully 
described in the text. 
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Amount rema~n~ng in 
body 24 hours after 
Time to reach last dose after 
T~ (hr) Y n (max) (mg) Yn(max) (hr) attaining Yn(max) (mg) 
ACTIVE 
CHLORAM-
PHENICOL 1.4 421 20 .. 2 0.004 
INACTIVE 
METABOLITES 1.1 2485 26.9 0.,027 
TOTAL NITRO 
COMPOUNDS 1.6 3200 27.9 0.035 
TABLE XXIII-B 
Maximum plasma levels (Yn(max)) of microbiologically active chloramphenicol, 
its microb i ologically inactive metabolites, and total nitro compounds, obtain-
able after initiation of therapy with a hypothetical daily dose of 50 mg/kg 
administered to a 70-kg human subject in equal doses every 6 hours. These 
data are based on calculations described more fully in the text. 
Number of Courses 
Patients with pancy topenia 
Patients with depression of 
one or two cell types only 
1 2 
15 11 
26 1 
TABLE XXIV 
3 Total 
5 0 1 32 
1 0 0 28 
Tabulation of numbers of courses of chloramphenicol given to patients 
who developed pancytopenia or depression of only one or two of the three 
blood cell t ypes. 
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Course of b 
PF 
a 
Therapy N r ?r (mgm/kg/day) (mgm/kg) 
Continuous & 
Intermittent, 33 +0.65 ..( .01 +0.65 <.OS 
( 120 days 
Continuous, 
(180 days 12 +0.91 < ·Ol +0.62 .( .05 51.17 
Intermittent, 
(120 days 22 +0.52 ( .05 +0.62 ( .05 58.48 
Intermittent, 
;;:>120 days 17 -0.18 ) .05 -0.03 ') .05 
Intermittent, 
<. 730 days 39 +0.18 ) .05 +0.01 > .05 
TABLE XXV 
Spearman rank difference correlation and linear regression coefficients 
for total dose and duration of therapy with chloramphenicol given to patients 
treated with various course schedules of the antibiotic and resulting in 
aplastic anemia. B is the number of patients in each group; ~ is the Spearman 
rank difference correlation coefficient; pr indicates the probability that the 
correlation coefficient is not statistically significant; ~ is the linear 
regression coefficient; PF indicates the probability that the plots are not 
linear; and ~ is the intercept, indicating the basic dose level used in these 
patients. 
Diseases 
for which 
drug is 
therapy 
of choice 
Side effects 
associated 
with drug 
CHLORAMPHENICOL 
Brucellosis 
Typhoid fever 
Rickettsial diseases (Rocky Mtn. 
Spotted Fever & endemic typhus) 
Aplastic anemia 
STREPTOMYCIN & DIHYDROSTREPTOMYCIN 
Tuberculosis 
(Impaired hearing 
(( Impaired hearing in patients 
with tuberculosis 
SM: 
NEOMYCIN 
Acoustic impairment 
Vestibular impairment 
Blood dyscrasias 
Acoustic impairment 
Vestibular impairment 
Blood dyscrasias 
Acoustic & 
Morbidity 
Rates 
per 100,000 
population 
indicated 
Ref-
er-
ence 
0.55 (U.S. 1959) (1) 
0.49 (U.S. 1959 (1) 
0.14 (U.S. 1959) (1) 
0.36 pts. treated (2) 
46.62 (u.s. 1959) (1) 
3287.25 (U.s. 1959) (1) 
1.39 pts. w./TB 
6440. 
2770. 
1730. 
6170. 
3480. 
1800. 
pts. treated 
pts. treated 
pts. treated 
pts. treated 
pts. treated 
pts. treated 
(3) 
(3) 
(3) 
(3) 
(3) 
(3) 
Vestibular i~pairment 1180.0 pts. treated (3) 
Blood dyscrasias 
TRIMETHADIONE 
Epilepsy (type unspecified) 
Neutropenia 
Blood dyscrasias 
Agranulocytosis 
secondary to 
drug therapy, 
MORTALITY RATE 
451. 
21000. 
(U.s. 1959 
pts. treated 
0.07 (Denmark, 
1951-57) 
(4) 
(5) 
(6) 
Per cent 
incidence 
of series 
of 1622 
cases of 
drug-
induced 
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blood 
dyscrasias (7) 
22.6% 
3.7% 
0.6% 
0.4% 
0.4% 
(continued on next page) 
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TABLE XXVI 
Morbidity rates for some diseases and the side effects associated with the 
drugs of choice for those diseases. 
Sources of data: 
(1) Nagan, P.S. (ed.), Medical Almanac 1961-62. Philadelphia, 
W.B. Saunders, 1961. 
(2) It has been estimated (Leikin, S.L., et al., Clin. Proc. Childrens 
Hospital, Washington, D.C., JL: 171, 1961) that 7,278,000 patients 
were treated with chloramphenicol in the U.S. in 1959. The exact 
morbidity is. not known, but the A.M . A. reports 367 patients that have 
developed aplastic anemia over the 14 years the drug has been 
available for clinical use (See #7 below). This estimate of the 
morbidity rate is, of course, a minimum. 
(3) These figures are determined by adding the total number of patients 
treated in the several series reported in the literature and the 
total number of treated patients who exhibited the side effect, not 
taking into account the daily dose, total dose or duration of therapy. 
(4) Based on incidence data in Cecil, R.L. & Loeb, R.F., ~Textbook of 
Medicine. Philadelphia, W.B. Saunders, 1959. 
(5) Based on data in Davis, J . P. & Lennox, N.G., ~ Pediat. 34: 273,1949. 
(6) Mosbech, J. & Riis, P. Acta Med. Scand. 166: 343, 1960. 
(7) Semi-annual Tabulation of Reports submitted to the Registry on Blood 
Dyscrasias of the Council on Drugs, American Medical Association. 
Vol. 6, No. 2, July 1962. 
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